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Abstract 
Common risk alleles identified through Genome-Wide Association Studies 
(GWAS) explain about 14% of familial breast cancer cases. However, GWAS do 
not identify causative variants in the risk loci and do not contribute to the 
understanding of risk mechanisms. All of the risk loci functionally analysed to date 
are cis-regulatory, i.e. polymorphisms that modify gene expression. Therefore, 
we hypothesize that cis-regulation is a central mechanism in breast cancer 
susceptibility. 
Differential allelic expression (DAE) is the most robust method to identify the 
effect of cis-regulatory single nucleotide polymorphisms (SNPs). Our group 
established a whole-genome DAE map for normal breast tissue, which we 
integrated with the GWAS data, to identify risk loci with greater potential to be cis-
regulatory. We identified 111 loci, with one of them in the 12q24 locus, containing 
an unpublished GWAS SNP, rs7307700, and 15 DAE SNPs. 
We performed in silico analysis to characterize the regulatory potential of 
candidate cis-regulatory SNPs (rSNPs) in breast cell lines, and in vitro analysis 
by electrophoretic mobility shift assay (EMSA) to explore interactions between 
candidate rSNPs and candidate transcription factors (TFs). Three candidate 
rSNPs, rs10773145, rs10846834 and rs12302714, overlapped regulatory 
elements and DNase I hypersensitivity sites, and were associated with the DAE 
observed for two transcribed SNPs (or DAE SNPs), rs7301263 and rs12581512. 
The candidate SNPs rs10773145 and rs10846834 were both located within 
known c-FOS and STAT3 binding sites, but showed small allelic differences in 
the ChIP-seq data. Since there was no ChIP-seq data for rs12302714, we carried 
EMSA analysis. Although we detected DNA-protein binding for both alleles of this 
SNP, no allelic differences were detected. We also analysed candidate SNPs for 
microRNA binding and the results suggested that a microRNA have preferentially 
binding to the alleles of candidate rSNP rs12302714. These results indicate that 
the DAE observed might not be explained by differential binding of TFs at the 
three candidate rSNPs and might be due to other regulatory mechanisms, that 
require further exploration, such as splicing and microRNAs. 
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Resumo 
O cancro da mama é uma das doenças oncológicas mais comuns, sendo a mais 
frequente causa de morte entre as mulheres. É estimado que uma em cada onze 
mulheres será diagnosticada com cancro da mama ao longo da sua vida. Trata-
se de uma patologia complexa cuja etiologia pode ser devido a fatores genéticos 
e não genéticos. Estima-se que 5% a 10% dos casos de cancro da mama são 
devido a fatores genéticos, no entanto, o conhecimento atual acerca do risco 
hereditável não explica cerca 50% destes casos familiares. Recentes avanços 
tecnológicos, nomeadamente nos microarrays de genotipagem, e nos Estudos 
de Associação no Genoma Inteiro (genome-wide association studies, GWAS) 
permitiram identificar um grande número de variantes associadas a risco para 
cancro da mama. Os GWAS são estudos divididos por fases, que analisam 
variações no genoma inteiro, com o objetivo de descobrir fatores genéticos de 
risco de doenças comuns na população, como o cancro da mama. 
As variantes cis-reguladoras são polimorfismos frequentes na população (>5% 
de frequência do alelo menos frequente na população), ao contrário das 
mutações (<1% de frequência na população). Estes polimorfismos têm a 
capacidade de regular a expressão de genes quando localizados em elementos 
reguladores, nomeadamente, promotores ou elementos intensificadores 
(enhancer), podendo afetar a ligação de fatores de transcrição e 
consequentemente, a regulação de determinado gene. 
Atualmente, 94 loci de suscetibilidade para o cancro da mama foram 
identificados através de GWAS, que explicam apenas cerca de 14% do risco 
para esta patologia. Até à data, foram estudados funcionalmente 13 loci, e os 
resultados sugerem que os polimorfismos analisados tinham como mecanismo 
de atuação a cis-regulação. Adicionalmente, do 94 loci somente um se localiza 
numa região codificante, com todos os outros a localizarem-se em intrões, 
regiões intergénicas e regiões sem transcrição detetável (“gene deserts”). 
Finalmente, os GWAS para além dos 94 loci de risco validados, produziram 
longas listas de loci com significância estatística muito elevada, que necessitam 
de ser priorizados para estudos de validação. 
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Com base nestas evidências, a nossa hipótese é que a cis-regulação é um 
mecanismo importante para o risco do cancro da mama e que a maioria dos 
polimorfismos associados ao risco para o cancro da mama ainda por descobrir 
poderão ser também cis-reguladores. 
Este trabalho foca-se nos polimorfismos de nucleótido único (SNPs) cis-
reguladores e, entre outras abordagens, estes SNPs cis-reguladores (rSNP) 
podem ser identificados através da análise de loci de características 
quantitativas de expressão (expression quantitative trait loci, eQTL) e da análise 
de Expressão Alélica Diferencial (differential allelic expression, DAE). A análise 
de eQTL permite fazer uma associação entre SNPs e a variação de expressão 
total de determinado gene. No entanto, o nível de expressão total está sujeito a 
fatores em trans (tal como o nível de proteínas com função de fatores de 
transcrição), para além dos fatores em cis (alterações na sequência, tal como os 
SNPs). DAE é um dos possíveis efeitos observados na presença de rSNPs em 
elementos reguladores, dessa forma, a análise de DAE permite comparar os 
níveis relativos de expressão dos dois alelos do mesmo gene em indivíduos 
heterozigóticos, utilizando um SNP transcrito (tSNP ou DAE SNP). Esta 
abordagem não só indica qual o alelo a causar DAE, como elimina o efeito de 
fatores trans, pois compara os níveis de transcritos dos alelos individualmente 
no mesmo contexto celular e haplótipos. 
Num trabalho anterior feito pela Prof. Ana Teresa Maia e colegas, desenvolveu-
se um mapa de DAE em 64 amostras de tecido mamário normal, que informa 
quais genes estão sob a influência de rSNPs.  O próximo passo será identificar 
os SNPs causadores de risco. Assim, os dados do mapa de DAE foram cruzados 
com os resultados publicados e não publicados de GWAS para cancro da mama. 
Este cruzamento de dados foi feito de acordo com a localização cromossómica, 
distância física (janelas de ±250kb entre o GWAS SNP e o DAE SNP) e padrões 
de desequilíbrio de ligação (linkage disequilibrium, LD) com o valor mínimo de r2 
= 0.4. Foram identificados 111 loci candidatos que contêm pelo menos um 
GWAS SNP e um DAE SNP e com forte potencial cis-regulador. Em 32 loci o 
GWAS SNP e o DAE SNP estavam em elevado LD, ou seja, os seus genótipos 
estavam fortemente associados. Como todos os loci estudados funcionalmente 
sugerem que o mecanismo causador de risco para o cancro da mama é a cis-
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regulação, e como todos os loci identificados, com exceção a um, encontram-se 
em regiões não codificantes (sugerindo que estão localizados em regiões 
regulatórias), selecionámos para análise funcional o locus 12q24, não publicado, 
para testar se este locus encontra-se também sob influência de rSNPs e validar 
este locus para o risco de cancro da mama. O GWAS SNP neste locus não 
atingiu o valor estabelecido pelo GWAS para passar a fase III, talvez por não 
estar em elevado LD com o rSNP causal. Desta forma, iremos testar se a 
integração do nosso mapa de DAE com os dados do GWAS relativos ao cancro 
da mama é uma boa abordagem para priorizar loci ainda por validar, com maior 
probabilidade de estarem sob influência de variantes cis-reguladoras, e 
consequentemente, mais prováveis a estarem associados ao risco para o cancro 
da mama. 
Este trabalho teve como objetivo: 1) validar um dos loci identificados, mas não 
validados, localizado na região 12q24, e confirmar a sua associação com o risco 
para o cancro da mama; 2) identificar e analisar funcionalmente as variantes com 
potencial a serem cis-reguladoras no locus 12q24; 3) testar se a nossa 
abordagem é um método eficaz para priorizar variantes candidatas a associados 
com risco. 
Começou-se por analisar o nosso mapa de DAE nesta região. A região do locus 
12q24 apresenta 15 DAE SNPs e um GWAS SNP, rs7307700, localizado no 
gene AACS. Para identificar e analisar possíveis variantes associadas ao risco 
e com potencial a serem rSNPs, foram feitas análises in silico. Os dados dos 
projetos HapMap e 1000 Genomes Project foram consultados para identificar os 
melhores candidatos a rSNPs em LD ≥ 0.4 com o GWAS SNP, sendo 
identificados 72 rSNPs candidatos. Para analisar estes candidatos, acedeu-se 
aos dados dos projetos ENCODE e Roadmap Epigenomics, que contêm 
informações sobre zonas de hipersensibilidade à desoxirribonuclease I (DHSs), 
imuno-precipitação da cromatina (ChIP-seq) para diversas modificações de 
histonas e fatores de transcrição, previsões alélicas de ligação de proteínas 
(PWM). No final desta análise, 12 rSNPs candidatos foram encontrados em 
sobreposição com DHSs e com regiões que contêm marcadores para elementos 
reguladores, com evidência de estarem ativos em linhas celulares mamárias, 
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sugerindo que esses podem ter um efeito funcional através da regulação da 
expressão de genes alvo., 
Para identificar as variantes que poderão estar a causar DAE no locus 12q24, 
testaram-se os níveis de expressão alélica dos 15 DAE SNPs com os genótipos 
dos 12 rSNPs candidatos. Dado o padrão de DAE demonstrado pelos DAE 
SNPs, pretendeu-se identificar os rSNP candidatos cujos homozigóticos não 
demonstrassem DAE nos DAE SNPs (i.e., SNPs transcritos), e cujos 
heterozigóticos apresentassem DAE nos DAE SNPs. Três dos 12 candidatos 
(rs10773145, rs10846834 e rs12302714) explicavam o DAE de dois DAE SNPs 
(rs12581512 e rs7301263). Para dois deles, rs10773145 e rs10846834, que se 
encontravam em completo LD um com o outro, existiam dados de ChIP-seq 
disponíveis que indicavam a ligação das proteínas STAT3 e c-FOS. No entanto, 
esses dados não revelavam diferenças de afinidade entre os alelos de cada 
SNP. Para o terceiro candidato, rs12302714, como não existiam dados de ChIP -
seq, procedemos com ensaios in vitro. Os resultados de EMSA (electrophoretic 
mobility shift assay) sugeriram que, apesar de haver ligação de proteína, não 
existiam diferenças de afinidade para os alelos deste rSNP candidato. De acordo 
com estes resultados, é possível que estes três candidatos estejam a afetar o 
DAE observado nos DAE SNPs do gene AACS por outro mecanismo que não a 
ligação diferencial de fatores de transcrição em elementos reguladores. Outros 
mecanismos possíveis incluem diferenças alélicas de produção de transcri tos 
alternativos (alelos a afetar o processo de splicing), ou de regulação por 
microRNAs. 
De seguida, analisou-se se havia alguma previsão de ligação preferencial de 
microRNAs aos alelos dos 72 SNPs candidatos. Em 17 dos 72 SNPs (incluindo 
o SNP rs12302714) houve previsões de ligação microRNAs com preferência a 
um dos alelos comparativamente ao outro. Posteriormente, analisaram-se os 
genótipos dos candidatos rSNPs, DAE SNP e GWAS SNP para a estrutura de 
LD nessa região e para identificação dos haplótipos, nas 64 amostras de tecido 
normal da mama, que poderão ser responsáveis pelo aumento ou diminuição da 
expressão dos genes. Foram identificados seis haplótipos comuns, estando dois 
haplótipos associados a diferenças nos níveis de expressão. Estes resultados 
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sugerem que talvez seja o efeito acumulativo de dois ou mais rSNPs a causar o 
risco para cancro da mama e o DAE observado nos DAE SNPs no locus 12q24. 
Em paralelo a este trabalho, um outro locus (5q14.2) foi funcionalmente 
analisado. Um dos candidatos rSNP identificados através da análise in silico, 
afeta diferencialmente a ligação de um fator de transcrição no gene ATG10, 
causando assim, DAE por cis-regulação. No entanto, o fator de transcrição que 
se liga preferencialmente a um dos alelos deste rSNP permanece por identificar.  
Em suma, o cruzamento dos nossos dados de DAE com os dados de GWAS foi 
uma boa abordagem para priorizar loci não publicados dos GWASes que estão 
sob influência de cis-regulação, e com potencial para ser associado ao risco, 
para validação para o risco de cancro da mama. Futuramente, mais análises in 
silico e in vitro deverão ser feitas, de modo a entender que outro mecanismo de 
regulação poderá explicar o DAE observado no locus 12q24, e que fator de 
transcrição poderá estar a regular a expressão do gene ATG10 (locus 5q14.2). 
Uma análise mais aprofundada da regulação destes genes poderá levar também 
à compreensão da biologia de predisposição ao cancro e contribuir para o 
desenvolvimento de terapias futuras, especialmente na área da medicina 
personalizada, baseada nos haplótipos que regem o DAE em cada indivíduo. 
Palavras-chave: cancro da mama; suscetibilidade; polimorfismos de nucleóticos 
únicos; variantes cis-reguladoras; expressão alélica diferencial. 
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1  Introduction 
1.1 Cancer overview 
1.1.1 Epidemiology 
Cancer is among the diseases with the highest incidence in the world, leading 
not only to a reduction in the patient's quality of life but also to a socio-economic 
decline. It is estimated that one in four males and one in five females will have 
severe cancer in their lifetime (American Cancer Society, 2016). Every year, 
worldwide, fourteen million people are diagnosed with cancer and eight million 
die, and 1/3 of these deaths are thought to be preventable. In Europe alone, there 
were 3.45 million new cases of cancer (besides non-melanoma skin cancer) in 
2012. Since cancer develops with age, these numbers tend to increase, as life 
expectancy becomes longer. Without further improvement at scientific and 
prevention level it is estimated that by 2030 death by cancer will increase 59% 
(Globocan, 2012). In Portugal, according to Globocan 2012, 49,174 people were 
diagnosed with cancer, with breast cancer being the most common malignant 
tumour, and the incidence is predicted to increase to 60,772 by 2030. 
 
1.1.2 Aetiology 
According to the World Health Organization (WHO), cancer corresponds to an 
uncontrolled growth and dissemination of cells. Normally, it is characterized by 
the accumulation of genetic mutations over time, in the same cell, mostly due to 
environmental factors that cause an abnormal and uncoordinated proliferation of 
the cell (Figure 1.1.2.1) (Jackson & Loeb 1998). In other words, the real problem 
in cancer is the uncontrolled ability of a single cell that carries a driver mutation 
to divide. 
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Figure 1.1.2.1 Carcinogenesis stages. Tumours are complex groups of cells, with high level of 
intra- and inter- heterogeneity. Each step reflects genetic changes that will lead to a cancer cell. 
It begins with alterations that will inactivate tumour suppressor genes and activate oncogenes, 
promoting uncontrolled proliferation of the mutated cell, leading further to metastasis. (Image 
taken from (Yokota 2000)). 
 
Carcinogenesis is a multistep process which begins with the acquisition of 
somatic mutations in (proto-)oncogenes or tumour suppressor genes, where 
activation/up regulation or loss of function, respectively, causes 
hyperproliferation, blocking of differentiation and inhibition of cellular death 
(apoptosis) (Osborne 2004). (Proto-)oncogenes are involved in the normal 
growth of a cell, coding for proteins that stimulate cell growth, proliferation and 
regulate apoptosis. However, when mutated they become oncogenes that are 
constitutively activated, leading to abnormal cell proliferation, anomalous 
expression of growth factors and their receptors, such as fibroblast growth factor 
(FGF) and fibroblast growth factor receptor (FGFR), respectively. Other 
examples of oncogenes are HER2, c-MYC, hTERT, EGFR, VEGFR and RAS. 
Tumour suppressor genes are important for the delay of the cell division and DNA 
repair. Normally, tumour suppressor genes act by inhibiting cell growth, 
promoting apoptosis. The deregulation of these genes prevents abnormal cells 
to die. Some examples of tumour suppressor genes are TP53, BRCA1, BRCA2, 
APC and RB1 (Lodish et al. 2000). 
Tumour cells progressively acquire characteristics that allow them to continue 
proliferating and developing malignancy. These characteristics are called the 
Hallmarks of Cancer, and were first proposed in 2000 (Hanahan & Weinberg 
2000): 
 Sustaining proliferative signalling 
 Evading growth suppressors 
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 Activating invasion and metastasis 
 Enabling replicative immortality 
 Inducing angiogenesis 
 Resisting cell death 
The same authors, in 2011, proposed four more new characteristics that are 
involved in the pathogenesis of cancer (Hanahan & Weinberg 2011). Since none 
of this new features have been validated, they are called emerging hallmarks: 
 Deregulating cellular energetics 
 Avoiding immune destruction 
 Tumour-promoting inflammation 
 Genome instability and mutation 
Cancer cells have the ability to invade the surrounding tissues and metastasize 
to distant location, affecting almost any body part. Several types of cancers can 
be prevented if avoided exposition to common risk factors, such as tobacco and 
obesity. Furthermore, a significant percentage of cancers can be cured by 
surgery, radiotherapy or chemotherapy if detected early (World Health 
Organization, 2016).  
 
1.2 Breast Cancer 
1.2.1 Pathogenesis, histological and molecular subtypes 
There are several risk factor that increase the susceptibility to develop breast 
cancer such as age, diet, genetics, familial history, infections and endocrine 
factors (endogenous and exogenous) (Abdulkareem 2013; Shah et al. 2014). The 
high heterogeneity, genetic instability and complexity makes the task to identify 
the biological mechanism that leads to breast cancer more challenging 
(Abdulkareem 2013). Different types of breast cancer have different aetio-
pathogenesis. Morphologically, breast is essentially constituted by fat tissue and 
mammary glands. Mammary glands are composed by ducts and lobes, which 
have smaller sections named lobules. The majority of breast cancers are called 
carcinomas, and depending on the localization they can be called in situ 
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carcinoma – when localized in the region where it began -, or invasive carcinoma 
- if it spread to the surrounding tissues. The initiation of the in situ carcinomas 
may be in the lobules – lobular carcinoma – or in the ducts – ductal carcinoma, 
being the ductal carcinoma in situ (DCIS) significantly more common than lobular 
carcinoma in situ (LCIS) (National Cancer Institute, 2016). Histologically, unlike 
LCIS, DCIS and invasive carcinoma have intra-tumour histological differences 
and can be divided in five and seven subtypes, respectively: 
 
Figure 1.2.1.1 Histological classification of breast cancer. Breast cancer can be catalogued 
into different subtypes, according to histological features and growth patterns. This system is 
currently used by clinicians to categorize the heterogeneity found in breast cancer. (Image 
adapted from Malhotra et al. 2010). 
  
Infiltrating ductal carcinoma (IDC) accounts for 70-80% of all invasive 
carcinomas. In the clinics, the pathologist analyses the nuclear pleomorphism, 
glandular/tubule formation and mitotic rate in IDC and ranks it according to 
grades: well differentiated (Grade 1), moderately differentiated (Grade 2) and 
poorly differentiated (Grade 3) (Malhotra et al. 2010). 
Microarray analysis allowed investigators to understand and establish a 
molecular profile of gene expression in a tumour (Eroles et al. 2012). Molecular 
characteristics on cancer cells helped improved personalized medicine, since the 
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same type of tumour is different between people and within the tumour, 
culminating with differences in patient survival (Malhotra et al. 2010). Depending 
on the molecular type of tumour, we can predict the response to a directed 
treatment (Shah et al. 2014). Breast cancer can be divided in five major molecular 
subtypes (Figure 1.2.1.2) based on gene expression of the tumours: ER+ 
(oestrogen receptor positive)/Luminal A, Luminal B, Basal-like, ERBB2-enriched 
(or HER2) and Normal Breast-like (Sorlie et al. 2001; Sorlie et al. 2003). 
 
 
Figure 1.2.1.2 Molecular classification of breast cancer. Breast cancer present different  
subtypes, according to intrinsic molecular characteristics identified by microarray analysis of 
patient tumour specimens. Image taken from (Sorlie et al. 2003). 
Luminal A is the most common subtype of breast cancer, representing 50-60% 
of total. It is characterized by an increase in ER (oestrogen receptor 1) expression 
and/or PR+ (progesterone receptor)/HER2- status, GATA binding protein 3 and 
oestrogen-regulated LIV-1. It is also associated to low-grade tumours and good 
prognosis (Eroles et al. 2012; Malhotra et al. 2010; Sorlie et al. 2001). 
Luminal B is less common than Luminal A, accounting for approximately 20% of 
all breast cancer, and it is known for having low levels of ER/PR receptors, being 
HER2 negative, with high levels of proliferation, and not having a good prognosis 
(Sorlie et al. 2001; Malhotra et al. 2010). 
ERBB2 is an oncogene that encodes for the transmembrane tyrosine kinase 
growth receptor ERBB2 that is part of the human epidermal growth factor receptor 
(HER/EGFR/ERBB) family. This gene is overexpressed in 20-30% of all breast 
tumours and is involved in cell proliferation survival, cell motility, and invasion. 
ERBB2 positive tumours, where the expression of this gene is amplified, are more 
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aggressive and, therefore, present a poor prognosis (Shah et al. 2014; Sorlie et 
al. 2001; Perou et al. 2000).  
Basal-like/triple-negative is characterized by the expression of keratin 5, 6 and 
17, integrin beta, fatty acids, laminin and for the absence of ER, PR and HER2 
expression. Accounting for 3-15% of all breast tumour, this subtype is associated 
with poor outcome due to the lack of treatment options (Sorlie et al. 2001; Perou 
et al. 2000; Badve et al. 2011; Sorlie et al. 2003). 
 
Normal breast-like show similarities with normal breast tissue, expressing genes 
related to the adipose tissue, and other none-epithelial cell types (Sorlie et al. 
2001). 
More recently, a study has examined gene expression and copy number in 2,000 
breast tumours, the METABRIC project (Molecular Taxonomy of Breast Cancer 
International Consortium), performing a new integrative clustering, based on 
gene expression and copy number data and the results suggested ten novel 
molecular subtypes, showed in Table 1.2.1.1 (Curtis et al. 2012). 
 
Table 1.2.1.1 Breast cancer subtypes classification according to the METABRIC project.  
This table was accomplished based on data presented by the METABRIC project (Curtis et al. 
2012). IntClust, integrative clustering; CNA, copy number aberrations.  
Subgroup Characteristics 
IntClust 1 17q23/20q cis-acting luminal B subgroup; relatively good 
outcome 
IntClust 2 High-risk ER+ subgroup; characterized by amplification of 
11q13/14, overexpressing genes like CCND1 and RSF1, both 
previously linked to breast and ovarian cancer; associated with 
poor prognosis. 
IntClust 3 Luminal A cases subgroup, enriched for histotypes that typically 
have good prognosis; characterized by low genomic instability. 
IntClust 4 Includes both ER-positive and ER-negative cases; 
characterized by low levels of CNA and good prognosis. 
IntClust 5 ERBB2-amplified subgroup; characterized by HER2 
enrichment (ER-negative) cases and luminal (ER-positive) 
cases; low prognosis 
IntClust 6 8p12 cis-acting luminal subgroup; characterized by 
amplification of 8p12 
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IntClust 7 Luminal A subgroup; characterized by 16p gain/16q loss and 
higher frequencies of 8q amplification 
IntClust 8 Luminal A subgroup; characterized by 1q gain/16q loss, a 
common translocation event 
IntClust 9 8q cis-acting/20q-amplified mixed subgroup 
IntClust 
10 
Basal-like cancer enriched subgroup; characterized by high 
genomic instability and cis-acting alterations, namely, 5 loss/8q 
gain/10p gain/12p gain; good long-term outcome 
 
These molecular characteristics are important biomarkers that can indicate the 
patient overall cancer outcome – prognosis biomarker – and the effect of a 
therapeutic intervention – predictive biomarker – in order to improve diagnosis 
and treatment for breast cancer (Oldenhuis et al. 2008).  
 
1.2.2 Epidemiology 
In 2012, nearly 1.67 million women were diagnosed with breast cancer worldwide, 
and almost 522,000 of these women died (ranking as the fifth cause of death 
worldwide), making breast cancer the most common cancer in women (Globocan 
2012). In the same year, 463,800 European women were diagnosed with breast 
cancer, from which 131,200 died (Ferlay et al. 2013). In Portugal, out of 6,088 
women diagnosed with breast cancer, 1,570 died. Unfortunately, these numbers 
have a tendency to increase and by 2050 it is estimated 3.2 million new cases 
per year worldwide. As expected, the incidence is higher in developed than in 
undeveloped countries, and this is related mostly to these countries’ lifestyle. It is 
estimated that one in eight women will have breast cancer during their lifetime, in 
which 89% have more than 40 years. This change in incidence can be also due 
to an increase in population-based screening, which leads to an early detection 
and decrease in mortality (Youlden et al. 2012). 
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1.2.3 Aetiology 
1.2.3.1 Environmental /Overall Risk factors 
Although screening through mammography does not prevent cancer, it reduces 
the risk of dying from cancer. Finding cancer at early stages, while asymptomatic, 
makes the treatment easier and increases long-term survival (Centers for 
Disease Control and Prevention, 2016). There are some factors that can be 
avoided and that contribute to an increase risk of breast cancer, such as exposure 
to carcinogenic substances (e.g. alcohol, tobacco and red meat), oral 
contraceptives, give birth at older age (after 40s), obesity and exposure to 
radiation. Investing in protective factors such as physical exercise, keeping a 
healthy diet, a healthy weight and breastfeeding may decrease the risk of 
developing breast cancer (Youlden et al. 2012; McPherson et al. 1994). It is also 
known that breast cancer is strongly related with age, and in fact, this disease 
affects mostly elderly women after menopause (>54 years). 
1.2.3.2 Genetic Susceptibility 
Genetic susceptibility is an increased probability of an individual to develop a 
disease based on their genotype. This genetic inheritance can be triggered by 
environmental factors, normally at late age. Genetic susceptibility can be 
classified according to the relative risk that the genetic variant confer and their 
frequency in the population (Figure 1.2.3.2.1) (reviewed in Ghoussaini et al. 
2013).  
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Figure 1.2.3.2.1 Breast cancer genetic susceptibility loci. The relative risks and risk allele 
frequency for each locus. Higher risk mutations have lower frequency on the population, while 
common modest-risk alleles confer only a small risk (Ghoussaini et al. 2013). 
  
Inherited factors increase the probability of an individual having cancer due to 
mutations on the germline cells. About 5-10% of breast cancers are due to 
genetic predisposition, affecting mainly younger people (Gage et al. 2012). 
Comparing with the general population, individuals with at least one first-degree 
relative with breast cancer are two or more times more likely to develop breast 
cancer. Multiple-case families include a positive familial history with: 
 At least three relatives, in the same side of the family, with breast or 
ovarian cancer 
 At least, one first-degree relative  
 At least one case per generation 
 At least one first-degree relative diagnose at a younger age (<40) 
(McPherson et al. 1994) 
Although those inherited autosomal dominant mutations represent a small 
amount of the causes for breast cancer, most of them have a significantly high 
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penetrance - meaning that the individuals that carry those genetic variants have 
high probability of expressing the phenotype. 
 
1.2.3.2.1  High-risk mutations 
Some tumour suppressor genes, such as STK11/LKB1, BRCA1, BRCA2 and 
TP53, are involved in the repair of damaged DNA. When any of these genes 
acquire loss-of-function mutations the resulting protein will not be produced or 
function properly (Apostolou & Fostira 2013; Ripperger et al. 2009). These high-
penetrance alleles increase the risk for developing breast cancer by 10- to 30-
fold, through the direct effect of the mutation. Although mutations in these genes 
are rare in the population (have low frequency, <1%), they confer a significant 
lifetime risk for breast cancer (>50%) (Figure 1.2.3.2.1) (Ghoussaini et al. 2013; 
Fletcher & Houlston 2010). Twenty five percent of the familial cases of breast 
cancer are explained by high risk mutations, being 16% due to BRCA1 and 
BRCA2 germline mutations (Van Der Groep et al. 2011). In fact, multiple-case 
family studies have shown that by the age of 70, approximately 80% of the 
carriers of germline mutations in BRCA1 and BRCA2 genes would develop this 
type of cancer (Milne & Antoniou 2011). The studies and approaches that allowed 
the identification of these mutations were: i) linkage analysis, that provides 
statistical evidence of the contribution of a variant or gene in the disease aetiology 
within families (Ott et al. 2015; Aloraifi et al. 2015); ii) positional cloning, which 
helps identifying the causal genetic mutations of diseases with simple Mendelian 
inheritance (Puliti et al. 2007); and iii) DNA resequencing of candidate genes 
(Fletcher & Houlston 2010). 
Indeed, there are studies that show the existence of differences in penetrance 
within the carrier families, suggesting that there are other factors, such as 
environmental and genetic modifiers, influencing the risk (Begg et al. 2009; Milne 
& Antoniou 2011; Ripperger et al. 2009). It has been described that 
polymorphisms can have an effect in genes, altering their expression, making 
them an important tool to predict the risk associated with cancer, and, 
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furthermore, this may lead to new therapeutic methodologies for breast cancer 
patients (Maia et al. 2012; Milne & Antoniou 2011). 
 
1.2.3.2.2  Moderate-risk mutations 
Genetics variants in ATM, CHEK2, PALB2, BRIP1, PTEN and CDH1, also 
involved in DNA repair, increase moderately the relative risk for breast cancer 
(approximately two-fold), conferring an higher probability of an individual to 
develop breast cancer in their lifetime of approximately ≥20% (Figure 1.2.3.2.1) 
(Ghoussaini et al. 2013; Hindorff et al. 2011). DNA resequencing of candidate 
genes for coding variation, using genetically enriched cases, allowed the 
identification of these variants (Fletcher & Houlston 2010). 
 
1.2.3.2.3  Common low-susceptibility alleles and GWAS 
These alleles are common in the population, with a minor allele frequency (MAF) 
of >5%, and confer a modest to low relative risk, corresponding to <1.5-fold and 
a lifetime risk of 10-20% (Figure 1.2.3.2.1) (Ghoussaini et al. 2013). These 
polymorphisms are usually found by genome-wide association studies (GWAS), 
that are a type of study that analyses DNA sequence variations through the entire 
human genome, aiming to identify genetic risk factors for diseases that are 
common in the population (Bush & Moore 2012; Knight 2014). For breast cancer, 
recent studies identified so far 94 loci, that explained about 14% of the inherited 
risk for breast cancer (Michailidou et al. 2015). Of the 94 loci, 13 were studied at 
a functional level and all suggested that these polymorphisms can modify the 
expression of genes in a allele-specific manner, namely MAP3K1, CCDC170, 
ZNF365, CASP8, CCDN1, FGFR2, MDM4 and can modify breast cancer related 
genes, such as BRCA1 and BRCA2 (Ghoussaini et al. 2013; Michailidou et al. 
2015; Ripperger et al. 2009; Maia et al. 2012; Glubb et al. 2015; Cai et al. 2011; 
Shephard et al. 2009; Wang et al. 2014; French et al. 2013; Meyer et al. 2008; 
Meyer et al. 2013; Wynendaele et al. 2010). Additionally, the underlying 
mechanisms of these susceptibility polymorphisms are still unresolved.  
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Single nucleotide polymorphisms (SNPs) are spread across the genome. GWAS 
use marker SNPs as genetic markers for a certain genomic region and allow the 
association between numerous SNPs and a specific phenotype or disease (Bush 
& Moore 2012), by using cases and controls samples. Under the assumption that 
when the GWAS SNP is not the causative genetic variant and that the actual 
causal SNP is in high linkage disequilibrium (LD) with the marker SNP, GWAS 
uses LD as a measurement to correlated the genotypes of two different SNPs 
(Figure 1.2.3.2.3.1). LD refers to when two or more markers on a chromosome 
are transmitted together within a population, during chromosome segregation in 
cell division, forming haplotypes. Thereupon, this non-random association 
between alleles at two or more loci, is commonly measured by two parameters - 
D prime (D’) and R square (r2) which compare the observed frequencies of co-
occurrence for two alleles in a population with the frequencies expected if the two 
markers were independent (Bush & Moore 2012; Morton 2005). D’ varies 
between zero and one, corresponding to linkage equilibrium when the 
recombination between two or more markers is elevated, and to linkage 
disequilibrium, when there is no recombination between the two markers. 
Coupled with D’, high values of r2 (also scaled between zero and one) indicate 
that the two markers transmit similar information. Therefore, it only takes one 
genotyped marker to find the allelic variation of the other (Bush & Moore 2012). 
 
Figure 1.2.3.2.3.1 GWAS approach for identification of the causal SNP. A GWAS marker 
SNP in strong LD with a common causal variant, the true responsible for the phenotype, will report  
the causal SNP. Image obtained and adapted from (Balding 2006). 
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In other words, GWAS uses a marker SNPs that report the association with 
another SNP when both are in strong LD with each other. In this way, most of all 
genome sequence is covered only with a small portion of known markers SNPs. 
More loci associated with risk are yet to be identified, and is expected to be due 
to common-low susceptibility alleles (Galvan et al. 2010). However, the 
polymorphisms associated to a certain phenotype found in a GWAS, are rarely 
the individual causative polymorphism, and therefore it is necessary to improve 
the current approaches to be able to find the true cause of the observed 
phenotype and the intrinsic mechanism (Knight 2014; Consortium 2015). 
 
1.3 Genetic Variation/Polymorphisms 
Comparing DNA sequences from different individuals, it has been estimated that 
in every few hundred bases there is a genetic polymorphism. Considering that 
there are 3.2 billion nucleotides in the human genome and that they can be 
responsible for alterations in gene expression, it is of extreme importance to study 
these variations effect on differences in treatment response and disease risk  
(Stoneking 2001). Unlike mutations, these variations are common, with >1% of 
allele frequency in the population (Torkamani & Schork 2008). 
Within DNA variations, the most common are SNPs (~90%), tandem repeat 
segments (minisatellite (10-100 bp) and microsatellite (1-6 bp)), and large and 
small duplications/deletions/insertions (Wang et al. 2005). SNPs are variations of 
one nucleotide in the DNA sequence with the ability to regulate gene expression. 
They can also be found in protein-coding regions, and depending on whether the 
SNP changes or not the encoded amino acid in the final protein it is classified as 
non-synonymous or synonymous, respectively (Torkamani & Schork 2008). 
Since SNPs are present in a significant proportion of human populations, they 
are considered common genetic variation. Also, most of the SNPs have two 
alleles and their frequency is represented by the minor allele frequency (MAF) 
rather than the more common allele frequency (the major allele) (Bush & Moore 
2012). 
 
14 
 
1.3.1 Cis-Acting Regulatory Variants 
Gene expression is regulated by environmental, epigenetic and genetic factors 
that act both in cis and in trans (Jones & Swallow 2011). Cis-regulation is the 
mechanism by which a variation in the DNA sequence affects the expression of 
a gene, by modulating the binding affinity of transcription factors, mRNA stability, 
methylation and splicing, for example. Meanwhile, trans-regulation relates to the 
effect of proteins regulating other gene expression, such as transcription factors. 
Variants in cis-regulatory elements, like promoters, enhancers, silencers and 
insulators can disrupt or enhance the binding affinity of transcription factors and 
can lead to unequal levels of transcription between the two alleles of a gene 
(Figure 1.3.1.1). 
 
 
Figure 1.3.1.1 Cis-acting regulatory variation causing differential allelic expression. a) A 
variant in a proximal promoter may prevent transcription factor binding altering expression of the 
allelic transcript. Transcript SNPs (markers) (shown here as black/white circles) can be used to 
determine transcript ratios. b) A variant in a distal enhancer site may prevent complex binding 
and affect transcription levels. Image adapted from (Jones & Swallow 2011). 
 
SNPs can be anywhere in the genome and may affect, for example, the binding 
affinity of proteins in an allele-specific manner. One of those examples, found 
through GWAS, is present in the risk-loci FGFR2, where it was shown in a 
functional analysis that the risk allele was associated with increased expression 
of this gene when compared to the common allele (Meyer et al. 2008). Another 
example is MAP3K1, whose risk alleles are also associated with increased gene 
expression (Glubb et al. 2015). MicroRNAs (miRNA) and methylation can also be 
affected by genetic alterations such as SNPs. miRNAs are small non-coding 
RNAs with approximately twenty two nucleotides, that regulate gene expression 
by binding to mRNA and preventing translation (synthesis of a protein) or by 
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promoting mRNA cleavage and destabilization (Liu et al. 2012). Roughly 3% of 
genes represent miRNA and 30% of coding genes can be affected by miRNA 
(Sassen et al. 2008). The presence of a SNP in the 3’UTR of a mRNA might affect 
the miRNA binding and, consequently, the mRNA translation (Liu et al. 2012). 
For example, it was shown that the target site of miR-125b, in the 3’UTR of the 
gene BMPR1B, which encode a kinase, contains a SNP (rs1434536) and that 
miR-125b differently binds to the C and T alleles of this SNP in breast cancer 
(Sætrom et al. 2009). 
As well as miRNA, chemical modification of DNA and histones is also involved in 
gene expression regulation. DNA is packed around histone proteins (H1, H2A, 
H2B, H3, and H4 histones) forming the chromatin, that can suffer modifications 
such as methylation, acetylation, phosphorylation, ubiquitylation and 
sumolyation, specifically on lysine residues (K) of histones H3 and H4 (Hellman 
& Chess 2010; Ellis et al. 2009; Handy et al. 2011). The histone code hypothesis 
refer that the expression of the DNA information is partially regulated by these 
modifications. This epigenetic regulation can be complex since each histone can 
be modified simultaneously with different histone marks at multiple sites. Each 
histone has different number of lysine (that can be mono-, di- or tri-methylated or 
acetylated), arginine (that can be methylated) or threonine/serine/tyrosine (that 
can be phosphorylated). Therefore, it is probable that every nucleosome in a cell 
presents different modifications. In fact, in a recent study where they analysed 39 
histone modifications in human CD4+ T cells, a group have shown that patterns 
of modifications can occur on the genome, and most of those modifications were 
associated with promoters and enhancers, suggesting a role of histone 
modifications in transcriptional regulation (Wang et al. 2008; Handy et al. 2011; 
Bannister & Kouzarides 2011). The DNA methylation usually occurs in CpG 
islands (areas in the DNA sequence rich in C (cytosine) and G (guanine) 
dinucleotides, found frequently in promoters), namely in the C nucleotide, and it 
might be associated with gene expression repression due to the steric inhibition 
of regulatory transcription complexes binding to DNA (Handy et al. 2011; Ellis et 
al. 2009). 
Also, the accessibility to the chromatin for transcription factor binding varies 
according to the chromatin states, that can be open (euchromatin) or compact 
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(heterochromatin). Thus, the chromatin state is controlled by histone 
modifications. Since active regulatory elements are located in regions with open 
chromatin, that is, accessible to the transcription machinery, these DNA sites are 
highly sensitive to DNase I, an enzyme that digests the DNA strand (Jin et al. 
2015). Therefore, if a SNP is present in a DNase I Hypersensitive site (DHS), it 
may cause differences in transcription factor binding between the two alleles and 
lead to different levels of expression (Schaub et al. 2012).  
  
1.3.2 Differential Allelic Expression 
As stated before, regulatory SNPs or rSNPs may lead to different levels of 
expression between the two alleles of a gene (Maia et al. 2012; Jones & Swallow 
2011).  
Currently, two approaches are used to detect these differences of expression, 
namely, expression quantitative trait loci (eQTL) and differential allelic expression 
(DAE). eQTL provide us information about overall expression (mRNA) of a gene, 
making association between markers of genetic variation with gene expression 
levels typically measured in tens or hundreds of individuals. One of the 
advantages of eQTL is that it allows the identification of new functional loci, 
through GWAS, without having previous knowledge of specific cis or trans 
regulatory regions. However, it does not inform us which allele is causing the 
difference on expression levels (Figure 1.3.2.1) (Pastinen 2010). On the other 
hand, DAE approach is an allele-specific study, and the differences in expression 
between the two alleles due to the presence of a rSNP, can be quantified in 
heterozygous individuals as a ratio of the expression of one allele compared with 
the other, using transcribed SNPs (DAE SNPs) as allelic markers (Figure 1.3.1.1 
and Figure 1.3.2.1). DAE also allows the elimination of environmental or trans-
factors that can modify both alleles, since it is focused on the transcribed alleles 
individually (Pastinen 2010). 
Indeed, our research group performed a whole-genome mapping of cis-regulation 
in normal breast samples using DAE, and these results suggest that 
approximately 87 % of genes expressed in normal breast tissue are affected by 
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regulatory SNPs (rSNPs) (Xavier et al, unpublished). Another study has used 
eQTL analyses with information from The Cancer Genome Atlas (TCGA), 
regarding gene expression in ER+ breast cancer. They conclude that 1.2% of 
gene expression variance was due to cis-acting SNP loci, which corresponded to 
189 out of 15,732 tested genes (Li et al. 2013). 
Therefore, here we focus on DAE studies, considering it is more accurate in 
detecting cis-regulatory loci and in mapping the causal regulatory variant (rSNP), 
enabling to identify which allele is conferring the up- or down-regulation of a 
specific gene. 
 
Figure 1.3.2.1 Differences between eQTL and DAE.  In eQTL, the overall expression is equal 
even though the gene is being cis-regulated. In contrast, DAE shows the intrinsic difference 
between the alleles, in individuals heterozygous for a regulatory variant. Image adapted from 
(Pastinen 2010). 
  
1.3.3 Previous work – DAE map in normal breast tissue 
Previous work developed by Professor Ana Teresa Maia and her colleagues, 
consisted in a DAE scan of the entire genome. This was accomplished using 
microarrays (Illumina Exon510S-Duo arrays), and 64 normal breast tissue 
samples, which were genotyped and quantified for allelic expression. The result 
was a whole-genome map of cis-regulated genes (86.8% of the autosomal 
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genes), with 49,461 DAE SNPs located in 11617 genes, in breast tissue (Figure 
1.3.3.1). 
 
Figure 1.3.3.1 Global cis-regulation map of breast tissue. This map gives us information about  
which genes are being cis-regulated and, therefore, presenting differential allelic expression  
(Maia et al, unpublished). 
The DAE measured in tSNPs (DAE SNPs) can be explained by the effect of an 
rSNP that differentially regulates their expression. Depending on the different 
levels of LD (measured by D’ and r2) between the rSNP and the tSNP, three 
patterns of DAE distribution can be seen in this map, consistent with the 
scenarios 1, 2 and 3 described by Xiao and Scott (Xiao & Scott 2011): 
 Scenario 1, if the tSNP is in complete LD (r2=1) with the rSNP. All 
heterozygous samples for the tSNP will show DAE (Figure 1.3.3.2. A) with 
the same allele being preferentially expressed. 
 Scenario 2, when the LD between the tSNP and rSNP is not complete, but 
strong (r2<1, D’=1). In this case, individuals heterozygous for the tSNP (Tt) 
might be homozygous (RR) or heterozygous (Rr) for the rSNP (Figure 
1.3.3.2. B), and therefore some heterozygotes for the tSNP will show DAE 
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(those heterozygous for the rSNP) and some will not (homozygous for the 
rSNP) 
 Scenario 3, when the tSNP and rSNP are in low LD (r2<1, D’<1), it is 
possible to find four combinations of the heterozygous tSNP with the rSNP 
in the population (Figure 1.3.3.2. C). Therefore, some individuals will not 
display DAE (the ones homozygous RR or rr for the rSNP) and others will 
display preferential expression of one or another allele (Rr or rR for the 
rSNP). 
 
 
Figure 1.3.3.2 Patterns for different LD measurements between rSNP and a heterozygous 
DAE SNP. Image taken from (Xiao & Scott 2011). 
 
Furthermore, with the aim to prioritize the best candidates for cis-acting regulatory 
SNPs in breast cancer, a member of our research group (Doctor Joana Xavier) 
cross-compared the DAE data (Maia et al, unpublished) with the published (94 
loci associated with risk for breast cancer) and unpublished (reported in a GWAS 
late phase) GWAS data. This integration was done by identifying loci that had at 
least a GWAS SNP and a DAE SNP within 250kb away from each other and with 
a minimum LD of r2 = 0.4. This generated a list of 111 clusters with strong cis-
regulatory potential in breast tissue, where in 32 of them the GWAS SNP and the 
20 
 
DAE SNP are in high LD. In the end, one cluster was prioritized – 12q24 locus – 
that contains a GWAS SNP that did not pass the last phase of the GWAS (with a 
p-value = 0.002), since the threshold was 1x10-7, not being associated to breast 
cancer risk. Since GWASes have a produce a list of unpublished SNPs to 
validate, the integration of our DAE data with the GWAS data for breast cancer, 
was also a way to prioritize the loci with genes being cis-regulated by cis-
regulatory variants, and therefore, more likely to be associated with breast cancer 
risk, for further validation studies. Therefore, we wanted to validate this 
unpublished locus to breast cancer risk, by identifying the cis-regulatory variants 
causing DAE, and further re-test the GWAS SNP with those candidate cis-
regulatory variants, in order to associate the 12q24 locus to breast cancer risk. 
This way, the aim of this study was to validate an unpublished GWAS locus to 
confirm it as a new risk locus for breast cancer. 
. 
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2 Hypothesis 
One of the limitations of GWASes is that they are unable to identify the true causal 
variant or the mechanism conferring risk for breast. Also, all variants found so far 
associated with risk for breast cancer were located in non-coding regions, 
suggesting that breast cancer associated variants may be mainly located in 
regulatory elements. To this date, 13 of the 94 loci were studied at a functional 
level by other research groups, and all of these causative SNPs were cis-
regulatory (Wynendaele et al. 2010; Ghoussaini et al. 2014; Gorbatenko et al. 
2014; Quigley et al. 2014; Glubb et al. 2015; Wang et al. 2014; Hurtado 2013; 
Dunning et al. 2016; Cai et al. 2011; Meyer et al. 2008; French et al. 2013; Huijts 
et al. 2011; Long et al. 2010; Cowper-sal et al. 2012). Thus, we hypothesize that 
cis-regulation is an important mechanism, contributing to the risk for breast 
cancer, and that cis-acting variants are responsible for the DAE observed. 
Additionally, GWAS have generated long lists of SNPs that were very close to 
reach genome-wide significance, and need to be validated to confirm their 
association with risk. Being DAE one of the effect observed in the presence of 
cis-regulatory SNPs, this makes it a powerful method to identify these SNPs. 
Therefore, integrating our DAE results with the GWAS unpublished and published 
data may be a powerful approach to prioritize loci to validate, with higher 
probability to be associated with risk for breast cancer and gene expression 
regulation. 
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3 Objective & Specific Aims 
For this master thesis, our main objective was to test if our DAE studies are a 
powerful tool to prioritize unpublished GWAS loci for validation studies, in order 
to help identifying further risk loci associated with breast cancer. Our specific aims 
were: 
1. To find new candidate cis-acting regulatory SNPs in the 12q24 locus; 
2. To functionally analyse their regulatory potential; 
3. To use them to validate the unpublished 12q24 locus and its association 
with breast cancer risk 
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4 Materials and methods 
4.1 Study samples 
In this work we studied a total of 290 samples. Eighty-four (84) samples were 
from normal breast tissue, extracted from women whose reduction mastectomy 
was performed for reasons not related to cancer. These normal breast tissue 
samples were collected at Addenbrooke’s Hospital, Cambridge, United Kingdom. 
Additionally, 150 samples of Human B cells (blood) were extracted from 
anonymous blood donors and 56 samples were extracted from cancer patient B 
cells (blood), both obtained from Blood Centre at Addenbrooke’s Hospital. All 
samples referred were acquired with the approval of the Addenbrooke’s Hospital 
Local Research Ethics Committee (REC reference 04/Q0108/21 and 
06/Q0108/221). 
DNA and total RNA was previously extracted from all samples using a 
conventional SDS/proteinase K/phenol method and TRizol® method, 
respectively. All extraction procedures were done at the University of Cambridge 
and the extracted RNA was used for DAE analysis. 
 
4.2 Cell lines 
In vitro assays were made with nuclear extract from breast cancer cell lines, 
namely, T-47D (human mammary ductal carcinoma, oestrogen receptor positive 
(ER+)), HCC1954 (human mammary ductal carcinoma, an oestrogen receptor 
negative (ER-)), MCF-7 (human mammary adenocarcinoma, (ER+)) and MDA-
MB-231 (human mammary adenocarcinoma, (ER-)) cell lines (Table 4.2.1). 
Nuclear extract from T-47D and HCC1954 cell lines were available in our stock. 
MCF-7 and MDA-MB-231 were cultured in DMEM medium at 37ºC and 
supplemented with penicillin/streptomycin to avoid contaminations and 10% 
foetal bovine serum, which is rich in growth factors, allowing the cells to grow, 
divide and survive. All cell lines were obtained from our collection.  
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The normal breast cell lines analysed in silico were HMEC (human mammary 
epithelial cells), HMF (human mammary fibroblasts), MCF10A (human mammary 
epithelial cells), BR.MYO (breast myoepithelial primary cells) and BR.H35 (breast 
variant HMEC). 
  
Table 4.2.1 List of breast cancer cell lines analysed. IDC, invasive ductal carcinoma; AC, 
adenocarcinoma; DC, ductal carcinoma. ER/PR/ERBB2/TP53/EGFR status: ER/PR positivity,  
ERBB2/EGFR overexpression and TP53 mutational status and protein levels. WT, wild-type.  
Information from (Neve et al. 2006) and ATCC website (www.lgcstandards-atcc.org). 
 
4.3 Linkage disequilibrium analyses and identification of proxy SNPs 
The publicly available tool SNAP (SNP Annotation and Proxy Search) was used  
to measure the LD between SNPs and for the identification of proxy SNPs. Proxy 
SNPs are SNPs in high LD that report each other. Thus, when a candidate SNP 
is not available on a particular genotyping array, proxy SNPs in LD with that 
candidate SNP can report it, based on observed LD patterns in the International 
HapMap Project (HapMap) and 1000 Genome Project (Johnson et al. 2008; The 
1000 Genomes Project Consortium 2012). Both projects were developed with the 
aim of identify and catalogue genetic variants with frequencies of at least 1% in 
the populations studied. We only use information of European (CEU) studies from 
1000 Genome Project and a maximum limit distance between the SNPs of 500kb 
(kilo-base). 
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4.4 In Silico annotation of variants functional information 
In silico annotation was performed in order to gather information regarding 
regulatory chromatin states, haplotype structures, DNase I Hypersensitive sites 
(DHSs), histone modifications, protein weight matrix previsions (PWM), 
microRNA binding predictions and chromatin immunoprecipitation sequencing 
(ChIP-seq), relatively to the candidate rSNPs. 
For our analysis, histone modifications were used to identify regulatory elements, 
since they are responsible for controlling the accessibility for protein binding 
(Table 4.4.1) (Handy et al. 2011). We also analysed DHSs data, since it is a 
powerful method to identify transcriptional regulatory elements and the chromatin 
states (Table 4.4.1). 
 
Table 4.4.1 Histone modifications. Examples of known histone modifications in breast tissue, 
where they are found genomically and some of their effect. Information gathered from Roadmap 
and UCSC Genome Browser in the scope of this work. 
Modifications Effect 
H3K4me3 Active promotor 
H3K4me1 Active and inactive enhancers – mostly 
intergenic regions 
H3K4me2 Active promotor 
H3K27me3 Repressive 
H3K27ac Active promotor and active enhancer 
H3K36me3 and H3K79me2 Transcriptional repression 
H3K9me3 Repeat repression 
H3K9ac Active mark 
 
ChIP-seq consists in a combination of two techniques, which are chromatin 
immunoprecipitation and sequencing. In this method, DNA-protein complexes are 
precipitated with a specific antibody that recognizes the target protein followed 
by DNA sequencing, allowing the identification of protein-DNA binding sites 
(Mardis 2007). We gathered information regarding ChIP-seq in Haploreg v4.1 
database and RegulomeDB. 
PWM is a probabilistic model that provides predictions concerning transcription 
factor binding consensus sites in a certain DNA sequence (Chen et al. 2007). It 
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is helpful when no ChIP-seq data is available for a certain locus or SNPs position. 
Haploreg v4.1 was accessed to consult PWM results. 
Besides these analyses, the following databases were accessed: 
 Haploreg version 4.1 (Ward & Kellis 2011) – it was used to access 
information regarding regulatory elements at variants on haplotype blocks, 
such as candidate regulatory SNPs at disease-associated loci. Using 
genotyping information from the 1000 Genome Project to analyse the LD 
structure in each locus, Haploreg provides information about SNPs that 
are highly correlated with the candidate SNP. Also, it gives information 
about PWM, chromatin state, sequence conservation across mammals, 
regulatory motifs of SNPs and DHSs. 
 UCSC Genome Browser (Kent et al. 2002) – it is a genomic browser that 
allows the visualisation of the genomic landscape of the candidate 
regulatory SNP concerning histone modifications, DHSs, chromatin state 
and transcription factor ChIP-seq. This interactive website gathers 
information from the Roadmap Epigenomics Project (Chadwick 2012) – a 
public resource of human epigenomic data such as DNA methylation, 
histone modifications, chromatin accessibility and small RNA transcripts in 
stem cells and ex vivo primary tissues – and the ENCODE Project (Encode 
Consortium 2012), regarding information about regulatory elements in the 
DNA, including ChIP-seq, DHSs and chromatin state.  
 Integrative Genome Viewer (IGV) – it is a high-performance visualization 
tool for interactive exploration of large, integrated genomic datasets 
(Robinson et al. 2011; Thorvaldsdóttir et al. 2013). Here, we analysed the 
results of several ChIP-seq experiments, to verify the intensity of the DNA-
protein binding and the binding affinity of the protein towards the two 
alleles of a heterozygous SNP (comparing the reads for each allele). 
 RegulomeDB (Boyle et al. 2012) – it is a website that collects information 
from Roadmap Epigenomics project and ENCODE project. Here, we 
analysed the candidate regulatory SNPs for known and predicted 
regulatory DNA elements including regions of DHSs, binding sites of 
transcription factors and promoter regions. 
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 Haploview software (Barrett et al. 2005) – it was used to analyse pair-wise 
LD and possible haplotype structure between the candidate SNPs, in our 
64 samples of normal breast tissue. 
 For microRNA analysis the following databases were accessed: 
 NCBI dbSNP (Sherry et al. 2001) – is a database of single 
nucleotide polymorphisms (SNPs) and multiple small-scale 
variations that include insertions/deletions, microsatellites. This 
database was used to obtain the sequence where each candidate 
SNP was located. 
 Ensembl (Yates et al. 2016) – is a genome browser with 
information, among others, sequence variation and transcriptional 
regulation. Ensembl tools include BLAST, BLAT, and the Variant 
Effect Predictor (VEP). This browser was used to find the location 
of the candidate SNPs in the gene in study. 
 miRBase database (Griffiths-Jones et al. 2008) – is a database of 
published miRNA sequences and annotation. Each entry in the 
miRBase Sequence database represents a predicted hairpin 
portion of a miRNA transcript (termed mir in the database). Here, 
we analysed the candidate SNPs for predicted microRNA binding 
sites. 
  
4.5 DAE mapping analysis 
DAE mapping analysis was done by plotting the DAE ratios (of the DAE tSNP) 
against the genotypes of the candidate rSNPs. Different statistical tests were 
used, depending on the DAE scenario observed. We used a t-test and Welch’s-
test to verify differences in DAE mean of the genotype groups, when variances 
were equal or unequal, respectively. We also used the F-test to verify differences 
in the variance between the homozygous and heterozygous groups for the 
candidate rSNP. We used permutation to correct the p-values. If the p-value is 
true, even when a 1000 permutation is applied (i.e. a 1000 combinations of the 
same samples) the outcome/results will be the same. With 1000 permutations the 
smallest possible p-value is 0.001, and the uncertainty p-value is 0.05. Genotype 
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imputation was performed by Doctor Joana Xavier, to cover more candidate 
regulatory SNPs, which consists in having reference haplotypes, obtained from 
HapMap and 1000 Genomes Project, and use it to predict genotypes at SNPs 
that were not directly assayed in individuals samples (imputation). In resume, the 
DAE mapping analysis was performed to analyse if the candidate rSNPs were 
associated with the DAE levels measured at the DAE SNPs. 
The DAE ratio was calculated, both in cDNA (complementary DNA) and gDNA 
(genomic DNA), using the formula: 
𝐃𝐀𝐄 =  𝒍𝒐𝒈𝟐 (
𝑨𝒍𝒍𝒆𝒍𝒆 𝑨
𝑨𝒍𝒍𝒆𝒍𝒆  𝑩
). 
The gDNA was used to normalize the results, excluding other events in the DNA 
sequence, such as copy number variations, that might be also causing unequal 
levels of expression between the alleles of a gene, and in this work we only focus 
on cis-regulatory variants. 
𝐍𝐨𝐫𝐦𝐚𝐥𝐢𝐳𝐞𝐝 𝐃𝐀𝐄 = DAEcDNA - DAEgDNA 
Thus, this analysis results shows the DAE caused only by cis-regulation. 
  
4.6 Polymerase Chain Reaction (PCR) for genotyping rs111549985 
PCR is a technique that allows the amplification of a specific segment of the DNA. 
To perform this technique five components are necessary, namely the template 
DNA to amplify, primers to set up the beginning and ending of the fragment to be 
amplified, deoxynucleotides (dNTPs) that form the new strands of the PCR 
product, and DNA polymerase an enzyme that synthetizes the PCR product. It is 
composed by three phases (denaturation, annealing and extension) where 
temperature varies, and the final product will be billions of copies (amplification 
of each fragment: 2n, n = number of cycles) of a specific DNA fragment, which 
can then be separated based on its size, using agarose gel electrophoresis. The 
agarose gel electrophoresis consists in adding the PCR product (DNA fragments)  
in an agarose gel and applying electric current. This way, it is possible to separate 
the DNA products on the basis of size, allowing the determination of the presence 
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and the size of the PCR product after the addition of a DNA stain, in the agarose 
gel when exposed to UV (ultraviolet) light (Lilit Garibyan 2013). 
In this work, primers were designed to amplify the region containing the SNP 
rs111549985 (Table 4.6.1). The PCR was made using KAPA2G Fast ReadyMix 
PCR kit (from Kapa Biosystems) or KAPATaq HotStart (from Kapa Biosystems) 
to genotype 51 normal breast samples. Both master mixes were prepared 
according to manufacturer’s instructions. The cycles set up was: 95ºC/3min 
(initial denaturation), 95ºC/15sec (denaturation), 60ºC-58ºC/15sec (annealing), 
72ºC/2sec (extension) and 72ºC/0.3sec (final extension). Denaturation, 
annealing and extension steps were repeated for 30 cycles. The agarose gel was 
prepared in a final concentration of 1.5% in 0.5X TBE and the electrophoresis 
was carried for 40min at 100V. Four ng of genomic DNA from each normal breast 
tissue sample were used, and water was used as a negative control (a non-
template control). Three µL of RedSafe (DNA stain) was added to agarose gel 
solution and we used Bio-Rad ChemiDoc to visualize the gel, to confirm the 
amplification and to verify the presence or not of contamination. The samples 
selected to sequence (by Sanger Sequencing) were then purified with Exo/SAP 
Go – PCR Purification kit (from GRiSP Research Solutions). The samples 
concentration was measured in a Nanodrop 2000c Spectrophotometer (Thermo 
Scientific) and then diluted to 80ng/µL and 50ng/µL. 
 
 
Table 4.6.1 Primers sequence designed for PCR. In the table is represented the selected SNP 
of the 5q14.2 locus to analyse. The common allele is shown first and the minor allele is shown 
second. For each allele of this SNP, the forward (FWD) and the reverse (REV) sequences were 
designed. 
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4.7 Nuclear protein extraction 
The nuclear protein extraction was made using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagent kit (Thermo Scientific) following the protocol 
stated by the manufacturer. Briefly, after scraping the cells in culture, two 
reagents were added to the cell pellet – CER (cytoplasmic extraction reagent) I 
and II – which disrupt the cell membrane, release the cytoplasmic contents, and 
leave the nucleus intact. NER (nuclear extraction reagent) was then added to lyse 
the nuclear membrane yielding the nuclear components. The concentration of the 
nuclear extract was measured using the Qubit 2.0 (Invitrogen by Life 
Technologies) spectrophotometer, according to the manufacturer’s instructions. 
The nuclear extract was then used to test the protein binding affinity in the two 
alleles of the candidate rSNP rs12302714. 
 
4.8 Electrophoretic Mobility Shift Assay (EMSA) 
EMSA is an in vitro technique that allows the study of DNA and protein 
interactions. Under the observation that the electrophoretic mobility of DNA-
protein is slower than the free DNA, due to their molecular weight, in a non-
denaturing polyacrylamide gel, it is possible to obtain information regarding 
binding affinity (Hellman & Fried 2007).  
This method consists in labelling a double-stranded oligonucleotide with a 
fluorescent marker, such as biotin or radioactive isotopes, and adding it to a 
nuclear extract. If proteins bind to the labelled sequence, the formed complex will 
migrate slowly through the polyacrylamide gel when compared to the free 
oligonucleotide, producing a specific band of higher molecular weight (shift) 
(Figure 4.8.1). Additionally, an unlabelled oligonucleotide (competition reaction) 
can also be added to assess the binding specificity between the protein and the 
oligonucleotide. The unlabelled oligonucleotide will be used in a much higher 
concentration than the labelled oligonucleotide, and therefore if the protein is 
specific to that sequence it will bind more to the unlabelled oligonucleotide in 
excess, and the result will be a weaker band or no band. In a final test, to confirm 
which protein is binding to the oligonucleotide, an antibody that recognizes a 
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specific target protein, will create a heavier complex with less mobility, forming a 
band with higher molecular weight in the gel (supershift) (Figure 4.8.1) (Hellman 
& Fried 2007; Chorley et al. 2008). 
 
Figure 4.8.1 Illustration of EMSA technique. The gel shift assay consists in three major steps: 
1) binding reactions; 2) electrophoresis; 3) probe detection (Thermo Scientific, URL:  
http://www.piercenet.com/method/gel-shift-assays-emsa). 
  
4.8.1 Oligonucleotide Labelling and Detection 
The oligonucleotides were designed for both alleles of the candidate rSNP 
rs12302714 (C>T, 
TATGACTAACCTTTTGTAAACGGGTTGTGAGAGGCTGGGAG and 
TATGACTAACCTTTTGTAAATGGGTTGTGAGAGGCTGGGAG). An 
oligonucleotide that covers a region in the FGFR2 gene where Oct-1 and RUNX2 
proteins bind, was used as positive control (Meyer et al. 2008). The first step was 
to label each complementary oligonucleotide separately, and then proceed to 
annealing (10 minutes at 80ºC, then overnight at room temperature). The 
labelling was made with a non-radioactive marker, biotin, a molecule with the 
ability to intercalate specifically in the 3’ End DNA strands with the help of the 
enzyme terminal deoxynucleotidyl transferase (TdT). The labelling procedure 
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was executed following the manufacturer’s instructions of Biotin 3’ End DNA 
Labelling kit (from Thermo Scientific). To test the labelling efficiency, dot blot by 
hand spotting was performed. Before the detection process, the reactions were 
transferred from the gel in to a nylon membrane with the help of SD Semi-Dry 
Transfer Cell (from Bio-Rad), and then cross-linked using UV light. Further, the 
detection was made following the manufacturer’s instructions of 
Chemiluminescent Nucleic Acid Detection Module (from Thermo Scientific), that 
consists in blocking the membrane with Blocking Buffer (to block unoccupied 
binding surfaces), wash it with 1X Wash Buffer (to remove any impurities, 
reducing background signal during visualization) and adding a chemiluminescent 
substrate – luminol – for horseradish peroxidase (HRP), that permits the 
visualization of the labelled oligonucleotides when exposed to UV light. 
  
4.8.2 Protein-Nuclei Acid Binding and Competition Assay 
All EMSAs were performed following the LightShift Chemiluminescent EMSA kit 
(from Thermo Scientific). The reaction for each allele of the SNP and for the 
positive control (all at 30nM concentration) contained 1X binding buffer to 
produce ionic conditions that allow binding DNA-protein (preventing the pH from 
changing), 10ng/µL poly(dI.dC) which is a sequence composed only by I and C 
nucleotides where unspecific proteins bind, 1X protease inhibitor to protect the 
proteins from the digestive function of proteases, 1mM DTT to stabilize enzymes 
and other proteins, 10µg of nuclear protein extract and buffer C, all in a final 
volume of 20µL. The binding buffer and buffer C were prepared according to the 
Table 4.8.2.1. 
 
Table 4.8.2.1 Preparation of buffer C and 5X binding buffer, with a final volume of 1mL. BB, 
binding buffer. 
Buffer C 
Component 
Final concentration 
(in 1 mL) 
Hepes, pH 7.9 20 mM 
NaCl 400 mM 
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EDTA 1 mM 
Glycerol 20% 
H20   
    
    
5 X BB Buffer 
Component 
Final concentration 
(in 1 mL) 
Hepes, pH 7.4 100 mM 
ZnCl2 0.5 mM 
Glycerol 50% 
H20   
 
 
A 4 or 6% polyacrylamide gel was used to run the samples at 80V until the 
samples entered the lanes and then 120V for approximately 1h. The samples 
were then transferred to a nylon membrane, at 0.28A for 10min, cross-linked 
(exposure to UV-light two times, at 120mJ/cm2) and detected, as described 
previously. 
The results that showed clear evidence of differences in protein binding affinity 
between the two alleles of a SNP were further analysed with an EMSA 
competition assay. The competitions were performed by adding unlabelled 
oligonucleotide in different concentrations (1X, 33X and 100X, relatively to the 
30nM of the labelled oligonucleotide (considered 1X)) of the alleles of interest. 
For the alleles that continued to show protein binding with relatively high 
specificity, a supershift assay was performed by adding 2µL of specific antibodies 
(POL II and HMGA) at 200µg/0.1mL of concentration. 
5 Results 
5.1 Genomic view of the putative 12q24 risk locus for breast cancer 
Our DAE map was combined with the GWAS published and unpublished breast 
cancer data, in order to identify the loci that have at least a GWAS SNP and a 
DAE SNP within 250kb away from each other and with a minimum LD of r2 = 0.4. 
A list with 111 clusters with strong cis-regulatory potential in breast tissue was 
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generated, where in 32 clusters the GWAS SNP and the DAE SNP are in high 
LD. 
For this thesis we chose the locus 12q24, which in the GWAS study from Easton 
and colleagues (Easton et al. 2007) reached a p-value = 0.002 with an OR = 1.04, 
95% CI = 0.98–1.09). This level of significance was not sufficient for a genome-
wide study (threshold p-value ≥ 10-7), however it is high enough to suggest that if 
the region was analysed in more detail, and the true risk variants (if they exist) 
were identified, that the power to detect association with risk would be greatly 
improved. Thus, we aimed to test if the DAE method for identifying cis-regulatory 
variants was an efficient approach to prioritize the most promising candidates 
from unpublished GWAS lists.  
We began by analysing the region where the GWAS SNP rs7307700 is located 
(the 12q24 locus, more specifically, intron seven of the AACS gene, Figure 
5.1.1). According to our DAE map, there were 15 DAE SNPs that showed DAE 
in this locus, positioned in different genes, eight of which lie within the AACS gene 
and one in UBC gene (Figure 5.1.2). In this analysis, we focused on the region 
250kb upstream and 250kb downstream starting from the GWAS SNP rs7307700 
position. 
 
Figure 5.1.1 Genomic view of the GWAS SNP at the 12q24 locus.  In the top panel is 
represented an ideogram of chromosome 12, with the locus containing the gene AACS 
represented by a blue box. In the middle panel, genes are represented in blue and the AACS 
gene area is shaded in yellow. In the lower panel is represented the GWAS SNP rs7307700.  
Image obtained from Roadmap Epigenomics.  
 
35 
 
 
Figure 5.1.2 Genomic view of the tSNPs at the 12q24 locus.  In the top panel is represented 
an ideogram of chromosome 12, with the locus containing the gene AACS represented by a blue 
box. In the middle panel, genes are represented in blue and the AACS gene area is shaded in 
yellow. In the lower panel are represented the DAE tSNPs. Image obtained from Roadmap 
Epigenomics.  
 
5.2 Identification and analysis of candidate rSNPs in the 12q24 locus 
To find candidate cis-acting regulatory SNPs in the 12q24 locus, which could be 
hypothetically associated with risk, we searched for SNPs in moderate LD (r2 ≥ 
0.4 and D’≈1) with the GWAS marker SNP rs7307700. We chose this level of LD 
r2 ≥ 0.4 because we hypothesise that the GWAS SNP rs7307700 might not have 
passed the phase III of GWAS because it is not in high LD with the true causal 
variant. Seventy-two SNPs were met these criteria (Annex 1.2).  
We next prioritized the candidates that were located in regulatory elements and 
DHS sites. Of the 72 SNPs, 36 SNPs were overlapping regulatory elements with 
evidence for being active in breast tissue and, of these, 12 SNPs were also 
located in DHS sites (Table 5.2.1, 5.2.2 and Figure 5.2.1). 
Table 5.2.1 List of candidates rSNPs. Putative 12 rSNPs in moderate LD with the GWAS SNP, 
with evidence of being located in regulatory sites and DHS. Ref, reference allele; alt, alternative 
allele. MAF represents the frequency of the least common allele. These results were obtained by 
using SNAP tool, Haploreg v4 and RegulomeDB.  
SNP Alleles ref/alt MAF 
rs10846828 C/T 0.46 
rs12302714 C/T 0.41 
rs10846834 A/G 0.42 
rs10773145 T/C 0.42 
rs7133614 C/T 0.34 
rs10773146 G/A 0.42 
rs12578446 A/G 0.31 
rs34151902 G/T 0.27 
rs4765021 G/A 0.51 
rs4622332 C/T 0.41 
rs4559740 G/A 0.3 
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rs7294703 A/G 0.5 
 
To assess the chromatin context of the 12 candidate rSNPs, we also looked for 
histone modifications. These candidate SNPs were located in regions harbouring  
histone marks H3K4me1, H3K4me3, which are indicate enhancers and 
promoters, respectively, and H3K27ac and H3K9ac, which are markers for active 
regulatory elements. Figure 5.2.1 and Table 5.2.2 show these results. 
 
Figure 5.2.1 Genomic view of the 12 candidate rSNPs. In the top panel are represented the 
ChIP-seq data for a series of histone modifications (Green represents active marks, red is 
repressive marks) and DNase-seq experiments (in blue). In the middle panel are the 12 candidate 
rSNPs and in the lower panel are represented the genes in this region (blue). Image obtained 
from Roadmap Epigenomics. 
 
Table 5.2.2 List of candidates SNPs in AACS gene. In this table is represented the 12 
candidates rSNPs that were located in at least one promotor or one enhancer, with active histone 
marks in breast cell lines. T-47D (human mammary ductal carcinoma, oestrogen receptor positive 
(ER+)) and MCF-7 (human mammary adenocarcinoma, ER+) are breast cancer cell lines; HMEC 
(human mammary epithelial cells) and HMF (human mammary fibroblasts) are normal breast cell 
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lines. This table was made with results from Roadmap Epigenomics, Genome Browser, Haploreg 
v4.1 and RegulomeDB. 
 
 
5.3 Mapping analysis 
We next analysed the DAE distribution pattern of the 15 DAE SNPs located in 
this locus, in order to know their association with the candidate rSNPs genotypes 
(Annex 1.1).  For example, the DAE SNP rs12581512 presents a DAE scenario 
1 according to (Xiao & Scott 2011), with all except one heterozygote expressing 
more the A allele when compared to the G allele (Figure 5.3.1 A). This suggests 
that this SNP is most probably in high LD with the causal variant. rs7301263 
shows a scenario 2 pattern of DAE, where some (but not all) heterozygotes 
preferentially express the A allele when compared to the C allele (Figure 5.3.1 
B). 
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Figure 5.3.1 DAE distribution pattern of two DAE SNPs. In the top of each graphic is 
represented the DAE SNP and gene where is located. The x-axis represents the heterozygous  
genotypes of the two DAE SNPs meanwhile the y-axis represents the DAE ratio seen at these 
two DAE SNPs. (A) DAE ratio of the DAE SNP rs12581512 and (B) the DAE SNP rs7301263.  
Each green dot represents an individual heterozygous for the DAE SNP. The dotted lines are a 
threshold (0.58 to -0.58), defined by our group, for what we consider significant values (DAE ratio, 
log 2 (1.5) = 0.584). The samples observed in between the threshold have equal expression of 
both alleles, hence not causing a differential effect in expression. Above the dotted l ines are the 
samples in which one allele is being differentially expressed and below are the samples in which 
the other allele is differentially expressed. 
 
To test which candidates rSNPs could explain the DAE observed at the 12q24 
locus, we analysed the association between genotypes at the 12 candidate 
rSNPs and the DAE measured at the 15 DAE SNPs, by plotting the distribution 
of DAE of each DAE SNP according to the candidate rSNP genotype. Genotyping 
data used in this analysis came from our genotyping experiments, the DAE 
experiments and imputation exercises. The candidate rSNPs are only considered 
potentially causal and responsible for the DAE if: (1) the homozygous samples 
for the rSNP do not show DAE; (2) the heterozygous samples for the rSNPs 
present DAE.  
From this analysis, two candidate rSNPs showed greater potential to be the 
causal variant of DAE in AACS (DAE SNP rs12581512) – rs10773145 and 
rs10846834 – and one other candidate rSNP showed greater potential to be the 
causal variant of DAE in the UBC (DAE SNP rs7301263) - rs12302714 (Figure 
5.3.2 A and B). No variant explained the DAE observed in any of the remaining 
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genes from the 12q24 locus. Only some heterozygous for the candidate rSNP 
rs12302714 display DAE. But more importantly, we observed that all 
homozygous individuals for rs12302714, show equal levels of transcription of the 
two alleles of the DAE tSNP rs7301263. For SNPs rs10773145 and rs10846834, 
the majority of heterozygous individuals show one allele more expressed 
compared to the other. The Welch’s-test although not significant, was 
underpowered by the fact that there was only one homozygous sample for these 
SNPs, although, the DAE levels of the one homozygous sample and one 
heterozygous sample are near the cut-off. 
 
 
Figure 5.3.2 DAE mapping analysis for the candidate rSNPs rs12302714, rs10773145 and 
10846834. In the top of each graphic is represented the candidate rSNP, gene where it is located 
and p-value for this test. The x-axis represents the genotypes of the candidates rSNPs and the 
y-axis represents the DAE ratio seen at the DAE SNPs rs7301263 and rs12581512. (A) rSNP 
rs12302714 with DAE SNP rs7301263, (B) rSNPs rs10773145 and rs10846834 with DAE SNP 
rs12581512. The dotted lines are a threshold (0.58 to -0.58), defined by our group, for what we 
consider significant values (DAE ratio, log 2 (1.5) = 0.584). The samples observed in between the 
threshold have equal expression of both alleles, hence not causing a differential effect in 
expression. Above the dotted lines are the samples in which one allele is being differential ly  
expressed and below are the samples in which the other allele is differentially expressed.  
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5.4 In silico analysis of candidate rSNPs rs12302714, rs10773145 
and 10846834 
The rs12302714, rs10773145 and rs10846834 were located in the AACS gene 
(Figure 5.2.1). Since the three candidates rSNPs overlapped regulatory element 
regions, we searched for evidence of TF binding at their locations. No significant 
prediction of differences in allelic binding affinity was found for candidate rSNPs 
rs10773145 and rs12302714. For candidate rs10846834, PWM data analysis 
showed that several predicted TFs could have different allelic binding affinity 
(Tables 5.4.1, 5.4.2 and 5.4.3). 
Table 5.4.1 Predicted transcription factor binding for candidate rSNP rs10773145. TF, 
transcription factor. Information from Haploreg v4.1 database. The values represent PWM scores. 
Predicted TF binding Reference allele T Alternative allele C 
Sin3Ak-20 7.7 2.2 
 
Table 5.4.2 Predicted transcription factor binding for candidate rSNP rs10846834. TF, 
transcription factor. Information from Haploreg v4.1 database. The values represent PWM scores. 
Predicted TF binding Reference allele A Alternative allele G 
Gfi1 12.5 1.9 
Maf -1.1 10.9 
NF-E2 6.3 12.9 
Nrf-2 0.5 12.1 
 
Table 5.4.3 Predicted transcription factor binding for candidate rSNP rs12302714. TF, 
transcription factor. Information from Haploreg v4.1 database. The values represent PWM scores. 
Predicted TF binding  Reference allele C Alternative allele T 
Sox 11.8 11.1 
 
We next analysed ChIP-seq information for these three candidates. We found 
that rs10773145 and rs10846834, both located in an active enhancer at HMEC 
and BR.MYO cell lines (normal mammary cell lines), overlap a STAT3 and c-FOS 
proteins binding sites (Figure 5.4.1 and Figure 5.4.2). However, for rs12302714 
we were not able to find any evidence of TF binding in the ChIP-seq data available 
form ENCODE and Roadmap Epigenomics. 
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Figure 5.4.1 ChIP-seq results for (A) STAT3 and (B) c-FOS proteins in MCF10A cell line, at 
the candidate rSNP rs10773145. In the bottom of each image is represented the nucleotides,  
with adenine in green, thymine in red, cytosine in blue and guanine in orange. The horizontal bars  
correspond to the sequence reads of the experiment and the vertical bars to the frequency that 
the protein binds to each allele. The information was first obtained from Haploreg v4.1 and  
RegulomeDB and then visualised with IGV. 
 
Total Reads Count: 15 
C (Blue): 9 (60 %) 
T (Red): 6 (40 %) 
A 
Total Reads Count: 48 
C (Blue): 27 (56 %) 
T (Red): 21 (44 %) 
B 
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Figure 5.4.2 ChIP-seq results for (A) STAT3 and (B) c-FOS proteins in MCF10A cell line, at 
the candidate rSNP rs10846834. In the bottom of each image is represented the nucleotides,  
with adenine in green, thymine in red, cytosine in blue and guanine in orange. The horizontal bars  
correspond to the sequence reads of the experiment and the vertical bars to the frequency that 
the protein binds to each allele. The information was first obtained from Haploreg v4.1 and  
RegulomeDB and then visualised with IGV. 
For rs10773145 and rs10846834 candidate rSNPs the ChIP-seq results show 
strong binding of c-FOS in MCF10A cell line, but with small differences of affinities 
A 
Total Reads Count: 9 
A (Green): 5 (56 %) 
G (Brown): 4 (44 %) 
B 
Total Reads Count: 94 
A (Green): 44 (47 %) 
G (Brown): 50 (53 %) 
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between the two alleles (56% (C) and 44% (T) for SNP rs10773145; 47% (A) and 
53% (G) for SNP rs10846834). Regarding STAT3, the total number of reads (n ≤ 
20) of each ChIP-seq experiment was not sufficient to draw any conclusions. 
Therefore, it is likely that these SNPs do not alter the binding affinity of the 
transcription factors and might be causing the DAE observed in the DAE SNP 
rs12581512 by other mechanisms. 
Since there was no evidence of TF binding in the ChIP-seq data available, we 
decided to carry out an EMSA for the candidate rSNP rs12302714, to test if it 
could bind any other TF for which there was no ChIP-seq data available. 
5.5 Analysis of the protein binding preferences in the candidate rSNP 
rs12302714 
At the beginning of the EMSA experiments the oligonucleotide probes were 
labelled. This initial step included a labelling efficiency test, which was only done 
for the positive control (FGFR-13*). In Figure 5.5.1, it can be seen that this probe 
was labelled with 100% efficiency. 
 
Figure 5.5.1 Determination of labelling efficiency for Biotin Control DNA and for positive  
control annealed FGFR2. The blot includes the dilution for each of the standards of the 
Procedures for Estimating Labelling Efficiency (option 2: Dot Blot by Hand Spotting) (inside black 
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box); as well as the labelling control of the kit and the positive control of nuclear extract FGFR2 
(inside green box). 
Then, three different EMSAs were performed using three nuclear extracts from 
the breast cancer cell lines MCF-7 (Figure 5.5.2), T-47D (Figure 5.5.3) (both 
ER+) and HCC1954 (Annex 2.1) (ER-). As observed in Lane 1 of Figure 5.5.2, 
there is binding of Oct-1 and Runx2 to the control probe FGFR2-13*, which 
corresponds to the positive control of an rSNP regulating FGFR2 expression. The 
binding seen in Lanes 2 and 3 is not allele specific (contains oligonucleotides 
corresponding to the C and T alleles for this candidate rSNP, respectively). This 
equal binding was confirmed by the competition assays with the unlabelled 
oligonucleotides (Lanes 4-7), in which all bands disappeared, meaning that both 
alleles can compete with each other. Although, if there were differential protein 
binding preference between the C and the T allele of rs12302714, we would see 
a weaker band for one allele and a stronger one for the other allele. 
 
 
Figure 5.5.2 EMSA in vitro assay showing protein-nucleic acid interaction and competition 
binding studies. Nuclear extract from MCF-7 cell line were used. Lane 1 corresponds to the 
positive control, FGFR2 oligonucleotides, the band is identified by a circle. Lanes 2 and 3 (red 
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arrows) corresponds to labeled oligonucleotides containing the C and the T allele, respectively ,  
of the SNP rs12302714. Lanes 4 and 5 contains labeled oligonucleotide with the C allele, while 
lanes 6 and 7 contais the labeled oligonucleotide containing the T allele. For competition, 30 X 
higher concentrated unlabelled oligonucleotide was added to lanes 4 and 6, meanwhile to lanes 
5 and 7, the unlabeled oligonucleatide was set 100X higher. 
 represents the increase of oligonucleotide concentration. 
 
The EMSA was repeated using a different cell line T-47D (Figure 5.5.3) and in 
the same conditions, showing similar results. Therefore, it is possible that this 
candidate rSNP is causing the DAE observed in the DAE SNP rs7301263 by 
other mechanisms rather than alterations of the binding of transcription factors. 
 
 
Figure 5.5.3 EMSA in vitro assay showing protein-nucleic acid interaction of candidate 
rSNP rs12302714 with two different nuclear extracts. Nuclear extract from MCF-7 (black box) 
and T-47D (blue box) cell lines were used. Lane 1 corresponds to EBNA control; lanes 2 and 7 
contains the positive control FGFR2 oligonucleotides. Lanes 3, 4, 8 and 9 (red arrows) 
corresponds to labeled oligonucleotides containing the C and the T allele of the SNP rs12302714.  
It is important to say that, although it seems that there is more protein binding to the C allele,  
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those lanes (3 and 8) has more oligonucleotide pipetted that lanes 4 and 9 (which corresponds 
to the T allele). 
 
5.6 In silico analysis of microRNAs binding 
Since the results of ChIP-seq for the SNPs rs10846834 and rs10773145 and our 
EMSA results for SNP rs12302714 suggested that these candidate rSNPs might 
not be causing DAE by altering the binding affinity of transcription factors, we 
proceed to analyse if any of the initial 72 SNPs in LD with the GWAS SNP were 
causing DAE by altering the mRNA levels through differential allelic microRNAs 
regulation. 
The results suggested that 17 out of the 72 SNPs (including rs12302714) could 
modify the binding affinity of microRNAs to their targeting sites on 3’UTR of 
mRNAs, and could therefore, be affecting the mRNA levels in an allele-specific 
manner (Table 5.6.1). 
Table 5.6.1 List of SNPs predicted to be altering miRNA binding affinity. In this table is shown 
in the first column the 17 SNPs out of the 72 initial SNPs that alter miRNA binding affinity ; in the 
second column is the alleles of each SNP; in the third column is the miRNA that is  predicted to 
be binding differently to one allele compared to the other; and in the fourth column is the total 
number of miRNAs that binds to each SNP. This table was accomplished by consulting NCBI 
SNP, Ensembl and miRBase databases. 
SNP Alleles miRNA binding 
differently 
Total number of miRNA 
binding 
rs12302714 C - 11 
T hsa-miR-4506 
rs7133614  C hsa-miR-5708 8 
T - 
rs12578446  A hsa-miR-6747-5p 8 
G - 
rs4765021  A hsa-miR-6851-5p 4 
G - 
rs4765217  G hsa-miR-6866-5p 11 
T - 
rs56394386 A - 6 
G hsa-miR-5095 
rs4765218  A hsa-miR-4756-5p 12 
hsa-miR-4526 
G hsa-miR-3909 
rs7135489  A hsa-miR-5694 3 
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G - 
rs6488989  A - 16 
C hsa-miR-3691-3p 
rs2018130  C - 11 
T hsa-miR-1972 
hsa-miR-5708 
rs7955201 C hsa-miR-346 16 
T hsa-miR-3691-3p 
rs7138557 C - 7 
T hsa-miR-1245b-3p 
rs7137679 C - 17 
T hsa-miR-3613-3p 
rs900410 C hsa-miR-3162-5p 12 
T hsa-miR-4446-5p 
rs10846824 C hsa-miR-6810-3p 4 
hsa-miR-6845-3p 
T - 
rs55999005  C - 7 
G hsa-miR-873-3p 
T - 
rs7953077 C - 10 
T hsa-miR-19a-3p 
rs34624329  G - 24 
T hsa-miR-550a-3p 
hsa-miR-550b-2-5p 
hsa-miR-550a-5p 
hsa-miR-550a-3-5p 
rs12316499 A - 22 
G hsa-miR-3714 
hsa-miR-6885-5p 
rs7398636 C hsa-miR-1236-5p 20 
hsa-miR-3605-3p 
hsa-miR-6798-3p 
hsa-miR-6845-3p 
hsa-miR-6729-3p 
hsa-miR-4433a-3p 
hsa-miR-513c-3p 
hsa-miR-6891-5p 
hsa-miR-4433b-5p 
G - 
rs41473449  A - 2 
G hsa-miR-638 
rs11058031  A - 21 
T hsa-miR-1303 
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rs12303416  C hsa-miR-665 22 
T hsa-miR-5689 
rs58624919  A hsa-miR-4298 7 
G - 
rs10846822  C - 16 
T hsa-miR-1272 
 
5.7 LD structure and Haplotype analysis 
As there are three candidate rSNPs that can explain the DAE observed in this 
locus, we analysed the haplotype block and LD structure of the region using the 
genotype information of our 64 normal samples, in order to identify the haplotype 
containing the potential cis-regulatory variant or variants responsible for the DAE 
observed in the AACS and UBC genes. In other words, we analysed the 
frequency of the possible recombination between the alleles of the GWAS SNP 
rs7307700, the candidate rSNPs (rs10773145, rs10846834 and rs12302714) and 
the DAE SNPs (rs12581512 and rs7301263). 
Haplotype analysis showed that the region where the GWAS SNP, the candidate 
rSNPs and the DAE SNPs are positioned is divided in two haplotype blocks. The 
DAE SNP rs7301263 (located in the UBC gene) was not in high LD with the other 
SNPs. Meaning that random recombination may occur between the alleles of this 
SNP and the alleles of rs10773145, rs10846834, rs12302714, rs12581512 and 
rs7307700. Therefore, rs7301263 is not in a haplotype block, as we can see in 
Figure 5.7.1. 
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Figure 5.7.1 Linkage disequilibrium structure and haplotype blocks for the GWAS SNP 
(rs7307700, in green), the candidate rSNPs (rs12302714, rs10773145 and rs10846834, all in 
red) and the DAE SNPs (rs12581512 and rs7304293, in blue). In this LD plot, the blocks were 
defined using Confidence Intervals by Gabriel et al 2002. The SNPs are identified on top of the 
diagram. The r2 squared colour scheme was chosen, where black represent r2=1, the different  
shades of grey represent 0 < r2 < 1 and the r2 values inside the plots indicate the pairwise LD 
between the SNPs. Black triangles indicate the two haplotype blocks. Plot obtain from Haploview 
tool. 
 
Block 1 is about 10kb long and includes the candidate rSNP rs12302714 and the 
GWAS SNP rs7307700, meanwhile the block 2 (around 3 kb long) includes the 
DAE SNP rs12581512 and two candidate rSNPs, rs10773145 and rs10846834. 
Also, we observed that block 1 has 3 major haplotypes that account for 99.2% of 
the individuals (with some rarer not displayed in the figured), while block 2 has 
only 3 possible haplotypes, as shown in Figure 5.7.2. 
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Figure 5.7.2 Blocks 1 and 2 and their respective haplotypes. Above are the rsID. The 
frequency of each haplotype is shown at the right side and the SNP rsID on top corresponds to 
those in LD in Figure 5.7.1. In red are the candidate rSNPs, in green is the GWAS SNP and in 
blue is the DAE SNP. The haplotype 1 is constituted by C and G nucleotides; haplotype 2 by T 
and A nucleotide; haplotype 3 by C and A nucleotides; haplotype 4 by G, A and T nucleotides;  
haplotype 5 by A, G; and C nucleotides and haplotype 6 by G, G and C nucleotides of the 
corresponding SNPs. Image obtained and adapted from Haploview tool. 
The minor allele of the GWAS SNP rs7307700 (A allele, in green), which is 
associated with risk for breast cancer, is present in haplotypes 2 and 3. From our 
DAE data, the minor A allele of the DAE SNP rs12581512 (in blue), found in 
haplotype 5, is overexpressed when compared to the common G allele. 
The minor alleles of the candidate rSNPs rs10846834 (G) and rs10773145 (C) 
are found in haplotype 5 in block 2 (frequency approximately 30%) and the minor 
allele of rs12302714 (T) is found in haplotype 2 in block 1 (frequency 
approximately 40%). Interestingly, both haplotypes are in high LD and comprise 
the GWAS SNP risk allele (A) and the preferentially expressed DAE SNP allele 
(A). Also, the results from IGV suggested that the minor alleles of rs10846834 
(G) and rs10773145 (C) were associated with more binding affinity to STAT3 and 
c-FOS (Figure 5.4.1 and Figure 5.4.2), and results of microRNA analysis 
suggested that the miRNA hsa-miR-4506 binds preferentially to the T allele of 
rs12302714. This way, the effect of two or more alleles may be causing the risk 
for breast cancer and the DAE. 
A more detailed analysis of the haplotypes (Table 5.7.1), suggested that the 
haplotype 2, that also have the minor T of the candidate rSNP rs12302714, is 
more frequently transmitted with haplotype 5 (26.2% of frequency), which have 
the allele more expressed from the DAE SNP (A) and the G and C minor alleles 
51 
 
of two candidate rSNPs, both associated with more protein binding. However, 
haplotype 2 is also transmitted with haplotype 4, with 13.6% of frequency, that 
have the DAE SNP (G) less expressed allele and rSNPs (A and G) alleles 
associated with less protein binding. 
The haplotype 3 is transmitted with haplotype 4, haplotype 6 (1.3% and 3.1% of 
frequency, respectively; both with the GWAS allele (G) not associated with risk, 
DAE SNP (G) less expressed allele and rSNPs (A and G) less associated with 
protein binding) and with haplotype 5 (1.9% of frequency). 
Thus, the ratio of signal of the haplotypes more probably to be causing risk 
(haplotypes 2 / 5 and haplotypes 3 / 5) compared with the haplotypes not causing 
risk (haplotypes 2 / 4, 3 / 4 and 3 / 6) is 28.1% to 18%. Therefore, this might 
explain why the signal detected for GWAS was not significantly strong to 
associate the GWAS SNP with risk for breast cancer, since 18% of the signal 
detected is from haplotypes recombination not associated with neither DAE and 
cis-regulation. 
Table 5.7.1 Blocks 1 and 2 and their respective haplotypes frequency recombination.  The 
frequency of each haplotype in our 64 samples is shown below each block. In the column 
“Frequency of recombination (%)” is represented in percentage the frequency of recombination 
between block 1 (Haplotypes 1, 2 and 3) and block 2 (Haplotypes 4, 5 and 6). This table 
correspond to Figure 5.6.2 although more detailed. Table obtained and adapted from Haploview 
tool. Hap, haplotype. 
BLOCK 1.  Frequency of recombination (%) 
Hap 1 (53.1%) Hap 4 (51.5%) Hap 5 (0%) Hap 6 (01.6%) 
Hap 2 (39.8%) Hap 4 (13.6%) Hap 5 (26.2%) Hap 6 (0%) 
Hap 3 (6.3%) Hap 4 (1.3%) Hap 5 (1.9%) Hap 6 (3.1%) 
BLOCK 2.    
Hap 4 (67.2%)    
Hap 5 (28.1%)    
Hap 6 (4.7%)    
 
5.8 EMSA for candidate rSNP rs111549985 of the 5q14.2 locus 
During this master thesis project, in parallel, we conducted another functional 
analysis in the 5q14.2 locus, where we demonstrated differences in protein 
binding affinity between the two alleles of a SNP. It is included here to show an 
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example of an rSNP displaying preferential allelic binding affinity, which was not 
detected in the locus 12q24 (Figure 5.7.1). 
In summary, the SNP associated with breast cancer risk in the GWAS was 
rs7707921 (OR = 0.94, p-value = 5x10-11). The 5q14.2 locus had three genes 
showing DAE, namely ATG10, RPS23 and ATP6AP1L. After in silico analysis, 
one candidate rSNP located in ATG10 gene showed a putative effect in 
transcription factor binding sites, rs111549985 (data not shown since was 
performed by another colleague). However, there was not enough functional 
information available to associate this SNP to the DAE observed in this locus So, 
we performed a PCR to genotype the candidate rSNP rs111549985 in 51 normal 
breast samples, in order to be possible to perform the DAE mapping analysis, 
which further indicated that this variant is associated with DAE levels at three 
SNPs, in the genes ATG10 and RPS23. 
Through EMSA in vitro assay, using MCF-7, MDA-MB-231 and HCC1954 cell 
lines, we verified that there is a protein binding to both alleles but preferentially to 
the C allele of rs111549985 rather than the G allele (Lanes 3 and 4), as shown in 
Figure 5.7.1. Therefore, rs111549985 is a good candidate to be the causal rSNP 
to the observed DAE in ATG10 and RPS23 and to be associated with the risk of 
breast cancer. This binding was confirmed with competitions assay using 
unlabeled oligonucleotides (Lanes 5-10). We further performed a supershift 
assay in order to identify the protein that was binding to rs111549985 using 
antibodies against POL II, E2F1 and c-MYC (the EMSA for the last two proteins 
is not shown in Figure 5.7.1), based on PWM analysis results. The results (Lanes 
11-14) showed that none of these proteins are the one binding to rs111549985.   
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Figure 5.8.1 EMSA in vitro assay showing protein-nucleic acid interaction and competition 
binding studies for candidate rSNP rs111549985 (5q14.2 locus). Nuclear extract from MCF-
7 cell line was used. Lane 1 corresponds to EBNA control; lane 2 contain the positive control 
FGFR2 oligonucleotides. Lanes 3 and 4 (red arrows) corresponds to labeled oligonucleotides 
containing the C and the G allele of the SNP rs111549985. For competition, 1X concentrated 
unlabelled oligonucleotide was added to lanes 5 and 8; 30X higher concentrated unlabelled 
oligonucleotide was added to lanes 6 and 9; 100X higher concentrated unlabelled oligonucleotide 
was added to lanes 7 and 10. To lanes 11 and 13, HMGA antibody was added as negative control,  
meanwhile in lanes 12 and 14 Pol II antibody was added. 
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6 Discussion and Conclusion 
Prior studies have shown that inherited genetic variants contribute to the 
regulation of gene expression and may increase the risk of developing common 
diseases, such as breast cancer (Ghoussaini et al. 2013; Michailidou et al. 2015; 
Ripperger et al. 2009; Maia et al. 2012; Glubb et al. 2015; Cai et al. 2011; 
Shephard et al. 2009; Wang et al. 2014; French et al. 2013; Meyer et al. 2008; 
Meyer et al. 2013; Wynendaele et al. 2010). The fact that all 94 common low-
penetrance loci identified by GWAS associated with risk for breast cancer were 
located in non-coding regions, intergenic region or gene deserts (except one loci 
that was located in a coding region), suggested that they are located in regulatory 
elements. Furthermore, since all loci studied at a functional level suggested that 
these genetic variants are conferring risk through cis-regulation, we hypothesize 
that cis-regulation is an important mechanism for breast cancer risk and that the 
genetic variants located in the remaining loci to analyse functionally are likely cis-
regulatory. Since GWASes have a long list of unpublished SNPs to validate, we 
combined our DAE data, with unpublished and published GWAS data for breast 
cancer in order to prioritize the loci with genes being regulated by cis-regulatory 
variants, and therefore, more likely to be associated with breast cancer risk, for 
further validation studies. This way, the main objective of this study was to 
validate an unpublished GWAS locus to confirm it as a new risk locus for breast 
cancer, by first identifying the causal genetic variant(s) cis-regulating this locus 
and further performing a new association study to improve the GWAS SNP 
significance to breast cancer risk. 
In previous work performed in our group the whole-genome DAE map was 
accomplished by using microarrays and comparing the expression of both alleles 
in 500K SNPs along the genome. Further, merging the DAE map with published 
and unpublished GWAS data, was generated a list of 111 clusters with strong cis-
regulatory potential in breast tissue. Each cluster defined as having at least one 
GWAS SNP and one DAE SNP within 250kb. In 32 of the 111 clusters, the GWAS 
SNP and the DAE SNP were in strong LD. One cluster was located in the 12q24 
locus, which was selected to be analysed under the course of this thesis, in order 
to test if we could validate the GWAS unpublished SNP (rs7307700) that did not 
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reach the phase III GWAS statistical significance threshold (p-value ≤ 1x10-5) with 
a p-value = 0.002, and further, associate this locus to breast cancer risk.  
Besides the GWAS SNP rs7307700, the 12q24 locus contained also 15 SNPs 
displaying DAE. rs7307700 is located in the AACS gene, which encodes for an 
enzyme called acetoacetyl-CoA synthetase. Although, the physiological role of 
AACS is yet unclear in humans, some studies suggested its involvement in the 
regulation of lipid metabolism and the metabolism of ketone bodies (Schug et al. 
2015). The ketone bodies are often used as an alternative resource of energy by 
tumour cells when undergoing starvation (Ohgami et al. 2003; Schug et al. 2015). 
One possibility for this locus not passing the phase III significance threshold in 
the GWAS could be because it is not in high LD with the causal variant. As stated 
before, GWAS uses marker SNPs that report the association with other SNPs 
when they are in strong LD with each other. In this way, if the GWAS SNP 
rs7307700 is not in strong LD with the true causal variant, this may diminish the 
signal detected for rs7307700 during the association analysis, and as a result, 
the locus was not be associated with risk. We believe that by first looking for the 
possible causal regulatory variant, which evidence from other studies suggests 
might be a cis-regulatory SNP(s), and further analyse the correlation between the 
GWAS SNP and the causal rSNP genotypes, would be a possible way to improve 
the statistical power to detect association with risk at this locus. 
Taking this into consideration, we chose to investigate SNPs that are in moderate 
to high LD with the GWAS SNP. Based on our DAE data, and on data available 
from regulatory genomic projects, we selected 12 candidate rSNPs that showed 
potential to be cis-acting regulatory variants. Since we had the genotypes of all 
12 SNPs in 64 normal breast samples from the DAE study, we tested if any of 
these candidates could explain the DAE observed by performing a mapping 
analysis. In other words, we tested the genotypes of the 12 candidate rSNPs 
against the allelic expression of the 15 DAE SNPs, in order to see if when the 
candidates rSNPs were heterozygous, the samples presented DAE at the DAE 
SNPs, and when the rSNPs were homozygous the samples showed no DAE. The 
DAE SNP rs12581512 showed a DAE distribution pattern that suggest a 
complete LD between rs12581512 and the rSNP (or rSNPs), and the rs7301263 
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DAE distribution pattern suggested a strong, although incomplete LD between 
rs7301263 and the rSNP (or rSNPs). From this analysis, three of the initial 12 
candidates SNPs, rs10846834, rs10773145 and rs12302714, were selected as 
candidates to be putatively regulating the AACS gene. 
6.1 Analysis of candidates rSNPs rs10846834 and rs10773145 
The candidate rSNPs rs10846834 and rs10773145 were strongly associated with 
the DAE SNP rs12581512, with the majority of individuals heterozygous for these 
two rSNPs showing DAE. Although the p-value was not significant (p-value = 
0.485), we should note the lack of homozygotic samples for these SNPs, which 
weaken the statistical analysis. Therefore, we included these two candidate 
rSNPs in our analysis. However, for the heterozygous individuals for DAE SNP 
rs12581512 there was only one sample homozygous for the rSNPs rs10846834 
and rs10773145. Therefore, to confirm if these two SNPs are truly associated 
with DAE levels, we need to increase the number of samples in the analysis to 
improve the statistical power. 
The next step was to look for evidence of protein binding on these two candidates. 
For the rSNP rs10846834 there were predictions of three proteins possibly 
binding to its sequence (Nrf-2, Maf and Gfi1) with significant differences in allelic 
binding affinity. The protein Maf - encoded by the oncogene Maf - is part of the 
basic leucine zipper (bZIP) family of transcription factors, which have a basic 
domain capable of binding to the DNA and a bZIP domain to form heterodimers 
with specific transcription factors, such as NF-E2 and Nrf-2 (Kannan et al. 2012), 
which might explain the predicted binding of all of those proteins. PWM analysis 
suggested that Maf binds to the alternative G allele (PWM = 10.9), but not to the 
reference A allele (PWM = -1.1). We further looked on IGV for ChIP-seq 
experiments that could confirm the PWM results, but for these proteins there were 
no experiments on breast cell lines. Since there was no ChIP-seq experiments 
for these four proteins on breast cell lines, in the future we propose EMSA 
analysis to validate PWM results, particularly for Maf protein. 
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For the candidate rSNP rs10773145, there were predictions of Sin3Ak-20 protein 
binding, though with no significant allelic differences in binding affinity between 
the reference T allele and the alternative C allele. 
Also, for both candidate rSNPs rs10846834 and rs10773145 we found in 
Haploreg v4.1 and in RegulomeDB, results of ChIP-seq experiments showing 
that these two SNPs are located in a region that has STAT3 and c-FOS proteins 
binding, in MCF10A cell line. We analysed these results on IGV, to verify the 
intensity of the DNA-protein binding and the binding affinity of STAT3 and c-FOS 
proteins towards the two alleles of the SNPs rs10846834 and rs10773145, by 
comparing the reads for each allele. Regarding STAT3 protein binding, both 
candidate rSNPs had less than twenty ChIP-seq reads count (a total 15 reads for 
rs10773145 and 9 reads for rs10846834), which can lead to uncertainties on the 
differences in allelic binding affinity between for each candidate rSNPs. 
Therefore, other functional studies are needed to confirm this binding. On the 
other hand, there was strong evidence of c-FOS protein binding at both SNPs, 
with a total of 48 reads for rs10773145 and 94 reads for rs10846834. However, 
it did not seem that the c-FOS protein had binding preference for either allele of 
SNP rs10773145 or SNP rs10846834. Nevertheless, it is known that c-FOS is a 
common co-factor of STAT3, as their DNA binding sites co-occur proximally 
together. STAT3 is a transcription factor that regulates gene expression, 
including the FOS proto-oncogene, involved in cell proliferation, differentiation 
and apoptosis, and therefore STAT3 is normally constitutively activated in cancer 
cells, playing a crucial role in carcinogenesis. c-FOS is a bZIP protein that 
dimerizes with proteins of the JUN family, forming the AP-1 transcription factor 
complex. This complex is also often regulated in cancer by STAT3, influencing 
tumour angiogenesis, inflammation and inhibition of apoptosis (Carpenter & Lo 
2014; Xiong et al. 2014). A recent study in T-47D breast cell line, showed the 
cooperative transcriptional interaction among STAT3, c-FOS and c-JUN (AP-1) 
on the CCND1 promoter (which the coding protein is essential for the cell cycle 
G1/S transition). It was shown that after drug stimulation of STAT3, this protein 
was recruited to the CCND1 promoter along with c-FOS and c-JUN. However, in 
the absence of the AP-1 complex the STAT3 recruitment was abrogated (Díaz 
Flaqué et al. 2013). Still, there is very limited information regarding STAT3 and 
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c-FOS interaction, especially in breast cancer tissue, and the discrepancy in the 
number of reads in the ChIP-seq experiments for c-FOS and for STAT3 did not 
allow us to draw any conclusions. These results may also be influenced by this 
interaction or by the endogenous levels of STAT3 protein. 
 
6.2 Analysis of candidate rSNP rs12302714 
The candidate rSNP rs12302714 was significantly associated with the DAE levels 
at SNP rs7301263, since a portion of the heterozygous individuals for 
rs12302714 display DAE and all individuals homozygous for rs12302714 showed 
no DAE for tSNP rs7301263. 
We next looked for evidence of protein binding on rs12302714. For this candidate 
rSNP, there was only prediction of Sox protein binding, but with no significant 
allelic differences in binding affinity predicted for its alleles.  
Additionally, there was no ChIP-seq data available for this candidate rSNP, so, in 
order to test if there was any preferential binding affinity between the alleles of 
rs12302714 we performed an EMSA assay. The results suggested that there is 
a capability to bind protein (shift), although with no allelic differences in affinity, 
as both bands for the C and T alleles appeared with similar intensity. We also did 
a competition assay that confirmed previous evidence of a non-preferential 
protein binding of both alleles. Therefore, the candidate rSNP rs12302714 is 
probably not the responsible for a change in transcription factor binding that could 
cause the DAE observed on tSNP rs7301263 located in the AACS gene. 
 
6.3 In silico analysis of microRNAs binding for the 72 SNPs 
We looked for the causal rSNP in the AACS gene and we found three candidates 
rSNPs (rs10846834, rs10773145 and rs12302714) that explained the DAE 
observed in the SNPs rs12581512 and rs7301263, although after functional 
analysis the ChIP-seq results for rs10846834 and rs10773145, and performing 
EMSA in vitro assay for the SNP rs12302714, the results suggested that the DAE 
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observed was probably not due to cis-regulatory SNPs altering the binding affinity 
of transcription factors. Therefore, we searched for evidence of cis-regulatory 
variants acting in different ways, for example, altering miRNA binding. This 
analysis showed predictions that 17 SNPs (including rs12302714) could alter 
miRNA binding affinity. Normally, miRNAs are associated to gene silencing 
through post-transcriptional binding to their target site (frequently in the 3’UTR of 
mRNA sequence), affecting the translation and the mRNA stability (Liu et al. 
2012; Humphreys et al. 2005). There are studies that showed that the presence 
of SNPs in miRNA target site may regulate gene expression in an allele-specific 
manner (Wynendaele et al. 2010). Thus, miRNA regulation may be the 
mechanism causing DAE in the AACS gene. The preferential binding predicted 
for miRNA hsa-miR-4506 to the T allele of the candidate rSNP rs12302714, may 
suggest the association of the A allele of this SNP with gene expression 
regulation, since hypothetically, the mRNA containing the T allele in the 3’UTR 
will be silenced. More functional analysis is needed to validate the miRNA results, 
such as, microRNA functional analysis, in order to confirm the difference in 
binding affinity between the alleles of the 17 SNPs, and further test exactly how 
it affects the AACS gene expression. 
 
6.4 LD structure and Haplotype analysis for rs7307700, rs12581512, 
rs10846834 and rs10773145 
In order to see if there is a haplotype more associated with risk for breast cancer 
we did a haplotype and LD structure analysis. The DAE SNP rs7301263 was not 
in high LD with the other SNPs, and therefore, was not in a haplotype block. The 
GWAS compared the frequency between cases and controls of rs7307700 minor 
A allele and identified an association with risk. Therefore, it is detecting the signal 
from haplotypes 2 and 3 that both have the GWAS risk allele. Both haplotypes 
contain the GWAS SNP A allele and, in combination with haplotype 5 (the one 
containing the DAE SNP allele A and the rSNPs alleles G and C), accounts for a 
total frequency of 28.1%. On the other hand, the haplotypes with the less 
expressed alleles but that had the GWAS A allele (haplotypes 2 / 4, 3 / 4 and 3 / 
6) represent a total frequency of 18%. Therefore, maybe the risk signal detected 
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from the GWAS A allele was not significantly strong due to this small difference 
in the ratio of signal of the haplotypes carrying the preferentially expressed 
alleles. If these are the true causative of risk, then haplotypes 2 / 4, 3 / 4 and 3 / 
6 could be masking the effect detected at rs7307700. This may suggest that the 
effect of two or more alleles may be causing the risk for breast cancer and the 
DAE. 
Additionally, haplotype 5 possess the minor alleles G and C of the candidates 
rSNPs rs10846834 and rs10773145, respectively, which were associated with 
more binding affinity to STAT3 and c-FOS proteins, suggesting that this haplotype 
is associated with these transcription factors binding, and perhaps, with more 
expression of the AACS gene, when these variants are found together. The 
preferential binding predicted for miRNA hsa-miR-4506 to the T allele of 
rs12302714, found in haplotype 2 together with the GWAS risk allele, may 
suggest the association of the A allele of this candidate rSNP with DAE. 
 
Therefore, more in silico and in vitro analysis are needed to try to explain the DAE 
in 12q24 locus, that could be due to other regulatory mechanisms not studied in 
this work, such as allele-specific splicing events, rather than transcription factor 
binding. Only after clarifying the mechanism behind the DAE present in 12q24 
locus we will be able to understand if this locus could also be associated with risk 
for breast cancer, by re-testing the rSNPs for association with risk. Thus, more 
analysis are needed to understand the DAE observed in the AACS and UBC 
genes, although we believe that the AACS is more probable to be associated with 
risk for breast cancer, since the allele more expressed of the DAE SNP located 
in AACS is part of the haplotype that includes the GWAS risk allele, whereas the 
DAE SNP located in UBC seems not to be associated with risk. In summary, our 
approach, combining the data of our DAE map with the GWAS breast cancer 
data, revealed to be a fine method to prioritize unpublished locus under influence 
of cis-regulatory variants, associated with the DAE levels, to further validation 
studies. 
In the future, performing an association study with these candidate cis-regulatory 
variants is fundamental to associate the 12q24 locus to breast cancer risk. 
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Further studies similar to this work will contribute to a better understanding of the 
biology underlying breast cancer risk, as well as contribute to future development 
of cancer prevention and treatment, improving personalized medicine.  
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Annex 1 
Annex 1.1 DAE SNPs reported in previous results obtained in microarray (Maia et al, 
unpublished). These are the 15 DAE SNPs that we chose to validate. The x-axis indicates the 
genotype (all heterozygous) and the y-axis indicates the normalised DAE ratio obtained. Dotted 
lines delimit the cut-off of preferential allelic expression ratio [log2(1.5) = 0.584].  
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Annex 1.2 List of the 72 proxy SNPs in LD ≥ 0.4 with the GWAS SNP. 12 SNPs (in bold) were 
in at least one active promotor or enhancer and in DHS, in breast cell lines. The rest of the SNPs 
were excluded from our analysis. 
SNP Active enhancer or 
promotor in breast 
cell line 
DNase I 
rs10846828 Yes Yes 
rs12302714 Yes Yes 
rs10846834 Yes Yes 
rs10773145 Yes Yes 
rs7133614 Yes Yes 
rs10773146 Yes Yes 
rs12578446 Yes Yes 
rs34151902 Yes Yes 
rs4765021 Yes Yes 
rs4622332 Yes Yes 
rs4559740 Yes Yes 
rs7294703 Yes Yes 
rs4765217 Yes Not in breast 
rs56394386 Yes Not in breast 
rs4765218 Yes Not in breast 
rs7970937 Yes Not in breast 
rs12371384 Not in breast Not in breast 
rs7135489 Not in breast No data 
rs1384556 Not in breast Yes 
rs6488989 Yes Not in breast 
rs2018130 Not in breast Not in breast 
rs7955201 Yes No data 
rs7138557 Not in breast Yes 
rs7137679 Yes No data 
rs900410 Yes Not in breast 
rs10846824 Not in breast No data 
rs55999005 Not in breast No data 
rs7953077 Yes Not in breast 
rs10400509 Not in breast No data 
rs58416336 Yes Not in breast 
rs2291247 Not in breast Not in breast 
rs2291248 Not in breast Not in breast 
rs34624329 Not in breast Not in breast 
rs3751181 Yes No data 
rs12581512 Yes Not in breast 
rs12316499 Not in breast Not in breast 
rs10846829 Not in breast Not in breast 
rs7398636 Not in breast Yes 
rs7136220 Not in breast Yes 
rs7133006 Yes Not in breast 
rs7133864 Yes Not in breast 
rs1080910 Yes Not in breast 
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rs34961756 Yes Not in breast 
rs41473449 Yes Not in breast 
rs35620656 Yes Not in breast 
rs12580221 Not in breast Yes 
rs11058031 Not in breast Not in breast 
rs2297478 Not in breast Yes 
rs12303572 Not in breast Not in breast 
rs57491100 Not in breast Yes 
rs57031290 Not in breast No data 
rs12303416 Not in breast No data 
rs12305181 Not in breast Yes 
rs35941060 Not in breast Yes 
rs58624919 Not in breast Yes 
rs900411 Not in breast Not in breast 
rs6488984 Not in breast Not in breast 
rs11058053 Yes Not in breast 
rs35933435 Yes Not in breast 
rs10773140 Not in breast No data 
rs7307545 Not in breast No data 
rs7315347 Yes Not in breast 
rs7954593 Not in breast No data 
rs10744191 Not in breast Not in breast 
rs10773142 Yes Not in breast 
rs4765214 Not in breast No data 
rs56255932 Yes Not in breast 
rs34107239 Yes Not in breast 
rs10846822 Not in breast No data 
rs1029075 Not in breast Yes 
rs7963307 Not in breast No data 
rs2343542 Not in breast No data 
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Annex 2 
Annex 2.1 EMSA for candidate rSNP rs12302714, showing no differences in binding affinity 
between the alleles, even in different binding conditions.  Nuclear extract from HCC1954 cell 
line was used. Lane 1 corresponds to EBNA control; lane 2 contain the positive control FGFR-13 
oligonucleotides. Lanes 8 and 9 corresponds to EBNA control conditions; lanes 10 and 11 is 
EBNA conditions but with less poly(dI dC); lanes 12 and 13 is our conditions (normal); and lanes 
14 and 15 is our conditions but without zinc. 
 
 
 
Annex 2.2.1 Different EMSA conditions used to test if: 1) the kit conditions are improved; 2) the 
concentrations of poly(dI.dC) could alter the binding process since more protein may bind to the 
poly(dI.dC) sequence instead of the oligonucleotide of interest; 3) zinc ions could affect the 
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binding process, since for the control kit EBNA no zinc is added to the reaction; 4) our conditions 
is more adequate for EMSA assay. 
 
 
 
 
